.9/L"H(A"L
.-4*.LD F KL09E:92L
Qe2ne"V`J'+n
^f)knL),n
*6Z7LIneE",Pn

[,n')PX-$-9'T/Z !J:Z

Z

Z

ZC!+Z

Z
@4 +'@( ,@ 
+.) 4@ )8'5!+51@ 
6 :@ .,51.''@ 52 
'@6.@ ;
'9
5@
4
5=@5.'7
 ' 6=@/
)
.& +6!4@
+@"
=@.@5
>   *@
+@

; 
5
)@<-@ #;,@#,@ .) +
5 .,@< 5@ )51.+!
?.(@.)0
2@< 5@
32./+)@ +@ (1,@ 2.)@	).+64@6.@ '44@5
+@ =
24@.@ 
@<$6@
.)0( 
6@ ,6
	

.)!,
'@  +5!.+4@%%4@
<97A9=L 	V`P'I&' 	
n 

bD),P[;?<,ni,*,In
AE="5"L"B">%L 5L)!#
B(E"L>";?"B"6DE+I"L
\f*ln-).Pn
n
n

 n
n,Z4,P?!I)Wn
 \,n
n
n

+' *+($"+ (+ (6(AE)H+'5$"BL *5.G "L(7L D&*AL>"H*A"L;>9E991L
%+ 9L
	Z

Z
3(6*AE=D(H"L
46$+9L%+9#L&+


Z'@J': 'BZ 	
	C!+Z
Z	Z
D"L9#L3*4*AE>E+J"L
'6$"L %9.L3" 53"7EL9L
92L!3+8+CD@E+J"L
'6$"L	+
E"L+
+%+
%+9#L.9/L
	 3+4,CD>D+J"L +
%

%  % 
Y+/HZ4.;-!5ZKQ%VZC?L?!?5Z+HZ '';ZHR3'!MZM?ZZ A''DZC'T/'UZ!!?C$-;*ZM?Z
L<$C$Z@E?!'%SC'HZ ,'Z!5/>-!5ZHMR$WZ @C?M?!?5Z-HZAR6-!5WZ F'*/HM'C'$Z ;$ZJ+'ZG'HR8MHZC!Z
&0H#7?H'$Z;%?CZ@S51H+($Z!!?C$-;*ZM?Z 	INC2';'!Z5?6Z ?6/!WZ?;Z -?'M+-!HZ;$Z/;Z
Z!?:A5/;!'Z U/O,ZAC'T/5-;*Z5UHZ ;$ZC(*R5L1?=HZ[COMPANY_003]
PP
D
[COMPANY_003][COMPANY_003]
PP
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
2(88)
PROTOCOL SYNOPSIS
A single blind, randomised, multi-centre, active controlled, tr ial to evaluate 
safety, tolerability, pharmacokinetics and efficacy of ceftazidime and 
avibactam when given in combination with metronidazole, compared with meropenem, in children from 3 months to less than 18 years of age with complicated intra-abdominal infections (cIAIs)
International Co-ordinating Investigator
, MD
[LOCATION_002]
Study site(s) and number of patients planned
A sufficient number of patients are to be randomised 3:[ADDRESS_415450] 
72 hours (3 full days, ie, 9 doses) of study treatment (ie, eval uable patients; at least 60 patients 
in the ceftazidime and avibactam [CAZ-AVI] plus metronidazole g roup and at least 
20 patients in the meropenem group).  
Patient recruitment will ensure that no more than 90% of evalua ble patients will have 
diagnosed complicated appendicitis in all cohorts combined.  Pa tients will be allocated to 1 of 
4 cohorts based on age. Randomisation will be stratified as follows:
ï‚·Cohort 1: At least 15:5 evaluable patients aged from 12 years to <18 years 
ï‚·Cohort 2: At least 15:5 evaluable patients aged from 6 years to  <12 years 
ï‚·Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 years
ï‚·Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 years, 
comprising Cohorts 4a and 4b as follows:
ï€­Cohort 4a: Patients aged from 1 year to <2 years
ï€­Cohort 4b: Patients aged from 3 months to <1 year[COMPANY_003]
[COMPANY_003]
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
3(88)Approximately  [ADDRESS_415451] patient completed Q3 2017
Study design
This study  will be a single blind, randomised, multi-centre, active controlled trial.  Patients 
aged from 3 months to less than 18 y ears with complicated intra -abdominal infections (cIAIs) 
will be randomised to 1 of 2 treatment groups (3:1 ratio): CAZ -AVI in combination with 
metronidazole versus meropenem. Randomisation will be stratified appropriately .  Patients 
aged from 3 months to <1 year (Cohort 4b) must have been born at term (defined as 
gestational age â‰¥37weeks).
Patients will r eceive intravenous (IV) treatment for a minimum of 72 hours (3 full day s, ie, 
9doses) before having the option to switch to an oral therap y as specified below.  The 
decision to switch to oral therap y is entirel y at the Investigatorâ€™s discretion, if the pa tient has 
good or sufficient clinical response, and the patient is tolerating oral fluids or food.
Patients will be assessed for safety  and efficacy  throughout the study , and blood samples will 
be taken for pharmacokinetic (PK) assessment.  The duration of each patientâ€™s participation in 
the study  will be a minimum of 27 days to a maximum of 50 day s after start of study  treatment 
(defined as the time point at which first dose of study  treatment is administered) at which time 
there will be a late follow -up ( LFU) assessment visit.  The L FU is to be performed [ADDRESS_415452] dose of an y treatment.
Objectives
Primary (Safety) Objective: Outcome Measure:
Evaluate the safety and tolerability of 
CAZ -AVI plus metronidazole given at the 
selected dose regimen versus meropenem in 
paediatric patients aged â‰¥3 months to 
<18years with cIAIï‚·Adverse events (AEs) and serious adverse events 
(SAEs) from the signing of the Informed 
Consent/Assent Form to the LFU visit (27 to 
50days after start of study treatment)
ï‚·Cephalosporin class effects and additional AEs 
(including, but not limited to seizures, 
Clostridium difficile -associated diarrhoea, allergic 
reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function)
ï‚·Clinical: vital sign s (pulse, blood pressure, 
respi[INVESTIGATOR_697], temperature), electrocardiogram 
(ECG), and physical examinations
ï‚·Laboratory: complete blood count with 
differential and comprehensive metabolic panel
ï‚·Creatinine clearance (CrCl) 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
4(88)Secondary Objective: Outcome Me asure:
Evaluate the descriptive efficacy of CAZ -AVI 
plus metronidazole versus meropenem in 
paediatric patients aged â‰¥3 months to 
<18years with cIAIï‚·Clinical Outcomes at End of 72 hoursâ€™ 
Treatment, End of Intravenous Treatment 
(EOIV), End of Treatment (EO T) and Test of 
Cure (TOC)
ï‚·Microbiological response at EOIV, EOT, TOC 
and LFU
ï‚·Clinical relapse at LFU
ï‚·Emergent infections
Evaluate the PK of CAZ -AVI in paediatric 
patients aged â‰¥3months to <18 years with 
cIAIï‚·PK data of ceftazidime and avibactam will be 
analysed separately
ï‚·Plasma concentration will be listed and 
summarised by [CONTACT_336323]
ï‚·PK parameters derived from population PK 
analysis and potential PK/pharmacodynamic 
(PD) relationships will be re ported separately
Target patient population
Patients aged from 3 months to less than 18 y ears with cIAI.  
Duration of treatment
The IV stud y treatment is to be given for a minimum of 72 hours (3 full days, ie, 9 doses).  At 
any time after a minimum of 72 hours of IV study  treatment has been received, there is an 
option to switch to an oral therap y, as specified below.  The decision to switch to oral therap y 
is entirely  at the Investigatorâ€™s discretion, if the patient has good or sufficient clinical 
respon se, and the patient is tolerating oral fluids or food. The total period of treatment (ie, IV 
drug or oral switch therapy ) is to be between [ADDRESS_415453] , dosage and mode of administration
The study  is single blind, ie, a Blinded Observer will not know the patientâ€™s treatment 
assignment and will conduct clinical assessments (including efficacy  and safety ).  There is no 
use of placebo to act as a treatment bl ind.
Intravenous CAZ- AVI infusions will be given at doses based on the age and weight of the 
patient with adjustment according to renal function: 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
5(88)Cohort Age range Body 
weightCAZ -AVI dose
CrCl â‰¥50 mL/minCAZ -AVI dose
CrCl â‰¥30 to <50 mL/min
CAZ -AVI must be administered as a 50 to 100 mL infusion (dependent on dose) over 2 hours 
every 8 hours (Â±30 minutes)
1112 years to 
<18yearsâ‰¥40kg 2000 mg ceftazidime/500 mg avibactam 1000 mg ceftazidime/250 mg avibactam
1112 years to 
<18years<40kg 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
216 years to 
<12yearsâ‰¥40kg 2000 mg ceftazidime/500 mg avibactam 1000 mg ceftazidime/250 mg avibactam
216 years to 
<12years<40kg 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
312 years to 
<6yearsAll 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4a21year to 
<2yearsAll 50 mg/kg ceftazidime /12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b26months to 
<1yearAll 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b23months to 
<6monthsAll 40 mg/kg ceftazidime/10 mg/kg avibactam 20 mg/kg ceftazidime/5 mg/kg avibactam
1Patients considered for entry into the study will be within the normal range of body  mass index ( BMI) for their age, (2 to <18).  A healthy weight BMI 
for this age group falls between the 5th percentile and â‰¤95th percentile according to height, w eight, and age.
2BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
6(88)The Investigator should follow the package insert for meropenem for dose modifications 
associated with renal impairment.
Patients whose CrCl drops below 30 mL /min should be withdrawn from study  therapy .  
Patients withdrawing from study  therap y can be administered alternative therapi[INVESTIGATOR_336281]â€™s choice, which should be recorded in the Case Report Form.  If possible, patients 
should still be followed for safet y.  Because the CrCl determination is only an estimate of 
renal function, in instances where the CrCl is approaching thresholds that would require 
intervention such as a dose change o r discontinuation of therapy  (ieCrCL approaching 50 or 
30
mL/min) , the Investigator should use his or her discretion in determining (ie confirming the 
value b y repeat testing, if feasible) whether an immediate dose change, a short period of 
continued observation, or discontinuation of therapy  is warranted. If in the op
inion of the 
Investigator there is a clinically  significant reduction in a patientâ€™s estimated CrCl during the 
treatment period, then the Investigator should contact [CONTACT_336324] (immediate dose change, a short period of continued observation, or 
discontinuation of therapy ). Additionally , in instances of rapi[INVESTIGATOR_336282], the 
Investigator should increase the frequency  of CrCl monitoring, depending on the patientâ€™s 
clinical status, extent of renal function change and I nvestigatorâ€™s clinical evaluation.
The suggested dosing regimen of m etronidazole is10mg/kg IV over 20 to 30 minutes every  
8hours (Â±30 minutes) , but it can also be prescribed/adjusted by  [CONTACT_336325]. The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ -AVI infusion.
An optional switch to oral therap y is permitted on or after Stud y Da y 4 (ie, after 72 hours of 
IV study  drug) .  The decision to switch to oral the rapy is entirel y at the Investigatorâ€™s 
discretion, if the patient has good or sufficient clinical response, and the patient is tolerating 
oral fluids or food :
ï‚·Oral amoxicillin/clavulanic acid ( only in countries where its use for children is 
permitted; acco rding to local guidelines, administered at a dose and formulation per 
standard of care), or
ï‚·Oral ciprofloxacin ( only in countries where its use for children is permitted; according 
to local guidelines, administered at a dose and formulation per standard of care) plus 
metronidazole (administered at a dose and formulation per standard of care), or
ï‚·Pathogen -based therapy (in discussion with the Medical Monitor) .  The choice of oral 
antibacterial agent for pathogen -based therapy  will be driven by  [CONTACT_109972] a 
susceptibility  test, which will be provided tothe Investigator b y either the local or 
central labo ratory .  Initiation of pathogen- based therap y is at the Investigatorâ€™s 
discretion.
  Before administering pathogen -based therap y, the Investigator will discuss 
the results of the susceptibility  test and the selected antibacterial drug (which should be 
approved for use in children) with the Medical Monitor.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
7(88)The patient may  continue on IV study  drug for the entire duration of the study  therapy  (7 to 
15days), at the discretion of the Investigator.  
Comparator
Meropenem 20 mg/kg every  8 hours (Â±1 hour) given by  [CONTACT_336326]  
15 to 
30 minutes or up to 1 hour, or infusion duration as per local guidelines , with optional oral 
switch therap y as described above.  For patients weighing over 50 kg, the maximum dose of 
meropenem should not exceed 1 g every  8 hours.  
Statistical methods
Block randomisation using an interactive voice/web response s ystem will be used to assign 
patients in a ratio of 3:1 to the study  treatment groups of CAZ -AVI plus metronidazole or 
meropenem, respectivel y, in each of the cohorts for the age groups.  All study data will b e 
summarised within each age cohort separatel y and also overall (regardless of age cohort).
Safety data
The primary  objective will be to assess the safet y and tolerability  of CAZ -AVI plus 
metronidazole compared with comparator ( meropenem) .  Safet y data inc lude AEs, clinical 
laboratory  parameters, vital signs, ECG parameters, and phy sical examinations.  For each 
safet y variable, the last assessment made prior to the first dose of stud y drug will be defined as 
the baseline.  All safety  data collected from thi s study  will be summarised by  [CONTACT_336327] (ie, for CAZ
-AVI plus metronidazole versus meropenem irrespective of 
switching to oral therap y) for all patients who received an y amount of study treatment (termed 
the â€˜Safet y anal ysis setâ€™) ,and key data will also be summarised for those patients who 
received at least 72 hours of study treatment (termed the â€˜Safety  evaluable anal ysis setâ€™ ) by 
[CONTACT_336328].  Descriptive statistics will be produced to summarise the safety  data.  
Safety  data from this study  will be combined with those from another CAZ- AVI paediatric 
study  for complicated urinary  tract infections (D4280C00016) and will be presented in the 
same way .
The incidence of AEs and SAEs will be summarised by  [CONTACT_336329], according to the Medical Dictionary  for Regulatory  Activities vocabulary , by [CONTACT_6490].  The summaries will also be produced b y relationship to study  drug, and by  [CONTACT_336330] .  AEs leading to discontinuation from study  treatment will a lso be summarised.  
Summary  tables for clinical laboratory  tests, vital signs, ECGs, and ph ysical examination 
findings will be produced.
Descriptive efficacy data and patient characteristic/Baseline data
Efficacy  will be assessed descriptivel y in the inten
t-to-treat (ITT) set (all randomised 
patients) , the microbiological ITT (micro -ITT) set (all randomised patients who have a 
baseline pathogen known to cause cIAI), the clinically  evaluable (CE) anal ysis set (patients 
who meet minimal disease criteria for c IAI and all evaluability  criteria, including patients who 
received at least 72 hours of the intended dose and duration of IV study  drug, and for whom 
sufficient information regarding the infection is available to determine the patientâ€™s outcome ), 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Re vised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
8(88)and the m icrobiological lyevaluable (ME) analy sis set (patients who meet minimal disease 
criteria for cIAI and all evaluability  criteria similar to the CE anal ysis set, and have at least 
1typi[INVESTIGATOR_336283], ie, 
CAZ -AVI and meropenem) . 
Efficacy  will be assessed in the ITT, micro -ITT, CE , and ME analysis sets with respect to the 
proportion of patients with clinical response outcome of cure (at the end of 72 hoursâ€™ 
treatment, EOIV, the EOT, and the TOC visit) andclinical response outcome of relapse (at the 
LFU visit).  Favourable microbiological response will be assessed in the ME and the 
micro
-ITT analysis sets, and the number of patients with emergent infections (up to LFU) will 
be assessed in the ME analy sis set .  Patients in the ITT, micro -ITT, CE ,and ME anal ysis sets 
will be summarised according to the randomised treatment assignment .
Descriptive statistics (number, mean, standard deviation [SD], median, minimum, and 
maximum) will be provided for continuous variables, and counts and percentages will be 
presented for categorical variables.  All summaries will be presented b y treatment group.  
Demographic data and other baseline characteristic data will also be summarised.
Pharmacokinetic data
Pharma cokinetic assessment will be conducted for the PK anal ysis data set.  The data set will 
consist of all patients who will receive CAZ -AVI treatment, and have at least 1 ceftazidime 
and/or avibactam plasma measurement available. 
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by  
[CONTACT_336331].  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by  [CONTACT_336332] (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean Â±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 t o 4b will be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  The 
actual dosing and plasma sampling times will be used for the anal ysis.  The developed 
population PK model may be used to conduct simulations to determine probability  of PK/PD 
target attainment to help to justify  the CAZ -AVI dose regimens for paediatric patients with 
cIAI.  A stand- alone population PK modelling and simulation analy sis plan will be prepared 
andthe results will be reported in a stand -alone report outside of the clinical study  report.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
9(88)TABLE OF CONTENTS PAGE
TITLE PAGE ........................................................................................................... [ADDRESS_415454] OF ABBREVIATION S AND DEFINITION OF TERMS .......................... 14
1. INTRODUCTION ................................................................
................................. 16
1.1 Background and rationale for conducting this study ............................................. 16
1.2 Rationale for stud y design, doses and control groups ............................................ 17
1.3 Benefit/risk and ethical assessment ........................................................................ 17
1.4 Study  design ........................................................................................................... 22
2. STUDY OBJECTIVES .......................................................................................... 25
2.1 Primary  objective (safet y)...................................................................................... [ADDRESS_415455] ............. 33
3.10 Criteria for withdrawal ........................................................................................... 34
3.10.1 Screen failures ................................
........................................................................ 34
3.10.2 Withdrawal of the informed consent ...................................................................... 34
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
10(88)3.[ADDRESS_415456] AN AND TIMI NG OF PROCEDURES ............................................. 34
4.1 Enrolment/screening period ................................................................................... 39
4.2 Treatment period .................................................................................................... 40
4.2.1 Day 1................................................................
...................................................... 40
4.2.2 Days 2 and 3 ........................................................................................................... 41
4.2.3 Days 4 to â‰¤15 ................................................................
......................................... 41
4.2.4 End of IV treatment ............................................................................................... 42
4.2.5 End of Treatment (oral switch therap y)................................................................. [ADDRESS_415457] of Cure ............................................................................................................ 44
4.3.2 Late Follow -up................................
....................................................................... 44
5. STUDY ASSESSMENTS ..................................................................................... 45
5.1 Efficacy  assessments .............................................................................................. 45
5.2 Microbiological assessments ................................................................................. 45
5.2.1 Intra -abdominal fluid for microbiological culture ................................................. 45
5.2.2 Blood samples for microbiological culture ............................................................ 46
5.3 Safety  assessments ................................................................................................. 46
5.3.1 Laboratory  safet y assessments ............................................................................... 46
5.3.2 Physical examination ................................
............................................................. 48
5.3.3 Electrocardiogram .................................................................................................. 49
5.3.4 Vital signs .............................................................................................................. 49
[IP_ADDRESS] Pulse and blood pressure ........................................................................................ 49
[IP_ADDRESS] Body temperature ................................................................................................... 49
[IP_ADDRESS] Respi[INVESTIGATOR_2842]...................................................................................................... 49
5.3.5 Cephalosporin class effects................................
.................................................... 49
5.4 Other assessments .................................................................................................. 49
5.5 Pharmacokinetics ................................................................................................... 50
5.5.1 Collection of samples ............................................................................................. 50
5.5.2 Determination of drug concentration ..................................................................... 50
5.5.3 Storage and destruction of pharmacokinetic samples............................................ 50
5.6 Pharmacod ynamics not applicable ................................
......................................... 51
5.7 Pharmacogenetics not applicable................................
........................................... 51
5.8 Biomarker anal ysis not applicable ......................................................................... 51
5.9 Volume of blood .................................................................................................... 51
6. SAFETY REPORTING AND MEDICAL MANAGEMENT .............................. 52
6.1 Definition of adverse events .................................................................................. 52
6.2 Definition of s erious adverse event ................................
........................................ 52
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
11(88)6.[ADDRESS_415458] adverse event collection
............................................... 56
[IP_ADDRESS] Lack of Effect ......................................................................................................... 56
[IP_ADDRESS] Disease progression ............................................................................................... [ADDRESS_415459](s)................................
..................................... 60
7.2 Dose and treatment regimens................................
................................................. 61
7.3 Labelling ................................................................................................................ 63
7.4 Storage ................................................................................................................... 64
7.5 Compliance ............................................................................................................ 64
7.6 Accountability ........................................................................................................ 64
7.7 Oral switch therap y................................................................
................................ 64
7.8 Concomitant and other treatments ................................
......................................... 65
7.8.1 Drug -drug interactions ................................
........................................................... 71
7.8.2 Other concomitant treatment................................
.................................................. 71
8. STATI STICAL ANALYSES ................................................................................ 71
8.1 Statistical considerations................................
........................................................ 71
8.2 Sample size estimate .............................................................................................. 71
8.3 Definitions of anal ysis sets .................................................................................... 72
8.3.1 Safety  anal ysis set ................................................................
.................................. 72
8.3.2 Safety  evaluable anal ysis set .................................................................................. 72
8.3.3 Pharmacokinetic anal ysis set ................................................................................. 72
8.3.4 Efficacy  anal ysis sets ................................
............................................................. 72
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
12(88)[IP_ADDRESS] Intent -to-treat anal ysis set ...................................................................................... 73
[IP_ADDRESS] Microbiological intent- to-treat anal ysis set............................................................ 73
[IP_ADDRESS] Clinically  evaluable analy sis set ................................
............................................ 73
[IP_ADDRESS] Microbiologically  evaluable anal ysis set ............................................................... 73
8.4 Outcome measures for analy ses............................................................................. 74
8.4.1 Primary  outcome variables
..................................................................................... 74
8.4.2 Secondary  outcome variables
................................................................................. 74
8.5 Methods for statistical analy ses............................................................................. 74
8.5.1 Analy sis of the primary  variables .......................................................................... 74
[IP_ADDRESS] Adverse events ................................
....................................................................... 75
[IP_ADDRESS] Other safety  data .................................................................................................... 76
8.5.2 Analy sis of the secondary  variable(s) .................................................................... 76
[IP_ADDRESS] Pharmacokinetic outcome variables ....................................................................... 76
[IP_ADDRESS] Clinical outcome definitions ................................
.................................................. 77
[IP_ADDRESS] Microbiological response assessments................................................................... 81
[IP_ADDRESS] Emergent infections ................................
............................................................... [ADDRESS_415460] OF TABLES
Table 1 Study  plan detailing study  procedures ...................................................... 35
Table 2 Laboratory  safet y variables ...................................................................... 47
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 201 7
13(88)Table 3 Volume of blood per patient â€“ Cohorts 1 and 2
....................................... 51
Table 4 Volume of blood per patient â€“ Cohorts 3, 4a, and 4b ............................... [ADDRESS_415461] OF APPEN DICES
Appendix A Not applicable
Appendix B Additional Safety  Information 
Appendix C IATA 6.2 Guidance document
Appendix D Actions required in cases of combined increase of Aminotransferase and 
Total Bilirubin â€“Hyâ€™s Law
Appendix E Tanner Staging of Development
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
14(88)LIST OF ABBREVIATION S AND DEFINITION OF TERMS
The following abbreviations and special terms are used in this study  Clinical Study  Protocol.
Abbreviation or 
special termExplanation
AE Adverse event
AEoSI Adverse event of special interest
ALT Alanine aminotransferase
AST Aspartate aminotransferase
BAT Best Available Therapy
BMI Body mass index
CAZ -AVI Ceftazidime and avibactam
CE Clinically evaluable
cIAI Complicated intra -abdominal infection
CrCl Creatinine clearance
CRF Case Report Form (electronic/paper)
CRP C-reactive protein
CSA Clinical Study Agreement
CSR Clinical Study Report
CT Computed tomography 
cUTI Complicated urinary tract infection
DSMB Data and Safety Monitoring Board
ECG Electrocardiogram
EOIV End of Intravenous Treatment
EOT End of Treatment
ESR Erythrocyte sedimentation rate
GCP Good Clinical Practice
Î²-hCG ÃŸ-human chorionic gonadotropin
ICF Informed Consent Form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
INR International normalised ratio
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
15(88)Abbreviation or 
special termExplanation
International 
Co-ordinating 
InvestigatorIf a study is conducted in several countries the International Co -ordinating 
Investigator is the Investigator co -ordinating the Investigators and/or 
activities internationally. 
IP Investigational product 
IRB Institutional Review Board
ITT Intent -to-treat 
IV Intravenous
IXRS Interactive voice/web response system
KPC Klebsiella pneumoniae carbapenemase
LFU Late Follow -up
ME Microbiologically evaluable
MedDRA Medical Dictionary for Regulatory Activities
MIC Minimum inhibitory concentration
micro -ITT Microbiological intent -to-treat 
MRI Magnetic resonance imaging
MRSA Methicillin- resistant staphylococcus aureus
OAT Organic anion transporter
PD Pharmacodynamic
PK Pharmacokinetic
QT cB QT interval corrected using Bazettâ€™s formula
QT cF QT interval corrected using Fridericiaâ€™s formula
SAE Serious adverse event 
SAP Statistical Analysis Plan
SD Standard deviation
TOC Test of Cure
ULN Upper limit of normal
WBC White blood cells
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 M arch 2017
16(88)1. INTRODUCTION
1.[ADDRESS_415462] Class A, Class C and some Class D Î² lactamase -producing pathogens 
including those commonly  associated with complicated intra -abdominal infections (cIAIs) and 
complicated urinary  tract infections (cUTIs).  Avibactam, when comb ined with ceftazidime, 
has also been shown to be active against strains that express a combination of Î² -lactamase 
types, as well as strains that are concomitantly  resistant to other antibacterial classes such as 
fluoroquinolones.  
Beta-lactamase inhibitio n by [CONTACT_336333] a stable covalent 
carbamo yl linkage to the enzy me complex.  I t inhibited Class A and Class C Î² -lactamases b y 
50% at lower concentrations than other currentl y marketed Î² -lactamase inhibitors such as 
clavul anic acid, tazobactam, and sulbactam.  In addition, avibactam is a potent inhibitor of 
Class C enzy mes whereas clavulanic acid, tazobactam, and sulbactam lack any  activity  against 
this class of enzy mes.  Unlike currentl y available Î² -lactamase inhibitors, a vibactam does not 
induce Î² -lactamase production.  
Avibactam inhibited Klebsiella pneumoniae carbapenemase (KPC) -
2 Î²-lactamase in vitro and 
restored ceftazidime susceptibility  to Enterobacteriaceae -harboring KPC -2 or KPC -3 
Î²-lactamase ( Stach yra et al 2009).  The potent in vitro activity  of the ceftazidime and 
avibactam (CAZ -AVI) combination against Enterobacteriaceae -producing Class A, and 
Class C, Î²- lactamases has been confirmed in vivo in murine pneumonia, septicaemia, and 
pyelonephritis models.  
Currently  the options for the treatment of Gram -negative infections, especially  multi- drug 
resistant strains including extended- spectrum Î² -lactamase producers, are extremel y limited.  
Until recentl y, there have been no new investigational compounds under early or late 
development specifically targeted to combat these organisms.  Hence, the availability  and 
development of new agents to treat these infections will be a welcome addition to the existing 
treatments.  
Details of the CAZ -AVI clinical development programme to date can be found in 
Section 5.2.2 of the CAZ -AVI Investigatorâ€™s Brochure.  
The purpose of this stud y is to assess the safet y, tolerability  and d escriptive efficacy  of 
CAZ -AVI plus metronidazole versus meropenem in patients aged from 3 months to less than 
18 yearswith cIAI.  Data from this study  will be compared to similar data generated in adult 
patients so as to be able to extrapolate efficacy  and tolerability  to children.  The dosing 
regimen(s) has been chosen based on the paediatric pharmacokinetic (PK) study  and 
PK/pharmacod ynamic (PD) modelling of the exposure, required for the successful treatment 
of infections used in Phase 3 adult studies.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
17(88)1.[ADDRESS_415463] the Blinded Observer will assess the safet y and the 
clinical cure without bias.  Given the risk to patients and severit y of disease, a 
placebo
-controlled t rial would not be ethicall y appropriate.  
The study  is designed to include patients < 1 year of age who are born at term only  (defined as 
a gestational age â‰¥37 weeks).  Maturation during foetal life and after birth is a process 
involving all organs and functions of the growing human.  As such, all the main steps of drug 
disposition (absorpt ion, distribution, metabolism, catabolism, elimination/excretion) may  be 
under the influence of still incomplete morphological stages.  An incompletely  absorbed 
compound may  be less effective whereas a poorl y metabolized and/or excreted compound 
may result in an increased risk of toxicity .  Both risks will have to be evaluated.  Better 
understanding of the maturing kidney  should help to anticipate possible early  and late adverse 
effects of drugs in neonatal populations.  Nephrogenesis is completed b y the en d of 34th week 
of gestation and the kidney  of a full -term neonate (ie, between 37 and 41 weeks of gestation) 
possesses a full set of nephrons and adult levels of glomerular filtration rate are reached 
between 1 and 2 years of age.  Therefore, patients <1 y ear of age who were born pre -term are 
excluded from this study .
This study  will be conducted in hospi[INVESTIGATOR_336284] (IV) antibiotics.  The CAZ -AVI doses in this trial have been 
selected to achieve similar exposures reached in the Phase 3 studies in adults (D4280C00001 
and D4280C00005), with the intention of reaching the same level of efficacy (for further 
details regarding the dose selection rationale, please refer to the CAZ -AVI Inv estigatorâ€™s 
Brochure).
Complicated intra- abdominal infections are t ypi[INVESTIGATOR_336285], potentially  involving 
anaerobes such as the Bacteroides fragilis group.  Metronidazole will be added to CAZ- AVI 
to provide coverage for anaerobic organisms.  The spe ctrum of activity  of CAZ -AVI when 
combined with metronidazole is well suited to treatment of pathogens commonly  responsible 
for cIAIs.  
Meropenem is approved and widel y used for the safe treatment of cIAIs, and carbapenems are 
considered the drugs of choi ce for treating infections due to extended spectrum 
Î²-lactamase -producing Gram -negative bacilli.  The dose/regimen of meropenem tobe used in 
this trial is described in Section 7.
1.3 Benefit/risk and ethical assessment
This study  is the first study  with therapeutic intent for CAZ- AVI in children with cIAIs; 
however, the doses of CAZ- AVI have previously shown to achieve similar exposures in adults 
and chi ldren, so efficacy  of CAZ -AVI in children is likely .  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
18(88)Cohort 4 ( â‰¥3 months to <2 y ears) includes very  young patients (aged from 3 months to 
<6months) who are particularl y vulnerable in terms of lack of a ph ysiological reserve and 
rapid maturation of organs.  Therefore, in order to ensure that exposure (maximum 
concentration and area under the curve) was minimised in this group, while also still assuring 
robust predictions of sufficient exposure above the PK/PD target, Cohort 4 was divided into 
2parts for further anal ysis for dose selection: Cohort 4a (from 1 year to <2 years) and 
Cohort 4b ( â‰¥3 to <1 year).  This anal ysis indicated that a lower dose of 40 mg/kg 
ceftazidime/10 mg/kg avibactam reduces exposure in Cohort 4b, while still providing very  
high pre dictions of sufficient exposure above the PK/PD target ( â‰¥98% probability  of target 
attainment) in patients with normal renal function and patients with mild renal impairment. 
Thus, for the purposes of dosing in this study , Cohort 4 is split into Cohort 4a,who will 
receive the same dose as Cohort 2 (50 mg/kg ceftazidime/12.5 mg/kg avibactam, every  
8hours), and Cohort 4b, who will receive 50 mg/kg ceftazidime /12.5 mg/kg avibactam, every  
8hours for patients from 6 months to <1 year of age, and 40 mg/kg ceft azidime/10 mg/kg 
avibactam for patients from 3 months to <[ADDRESS_415464] been chosen on the basis of 
modelling and simulation to achieve similar exposures of both ceftazidime and avibactam to 
those in adults with normal or mild renal impairment and predictions of sufficient exposure 
above the PK/PD target.
Patients enrolled into this clinical study  will have cIAIs that are of sufficient severity  to 
require hospi[INVESTIGATOR_336286].  The potential benefit to patients 
participating in this study is that they  will receive effective antibiotic therapy  for their 
infection.  The potential benefit of this study , in general, is the identification of a novel 
antibiotic combination pro duct that is a safe and effective treatment for cIAIs in the paediatric 
population, in the face of the changing pattern of antibiotic resistance. The safet y and 
tolerability  of CAZ -AVI was established in a Phase 1 s tudy in children from 3 months to 
<18years, during which the exposures were similar to those observed in adults.
It is possible that CAZ -AVI may  not be as effective a treatment as the comparator for 
treatment of cIAIs.  Although this risk is mitigated partly  by [CONTACT_336334][INVESTIGATOR_336287] b y the Investigator 
providing treatment. Furthermore, drug -drug interaction studies conducted between CAZ -AVI 
and metronidazole did not demonstrate an y drug interaction or adverse safety impact.
A Phase 3, randomis ed, multice ntr e, double- blind, doub le-dummy, parallel-group, 
comparative study t
odeter mine the effi cacy, safe ty, and t olerability of CAZ- AVI plus 
metron
idazo le versus m eropenem was conducted in the tr eat ment ofcIAIs in hospi[INVESTIGATOR_336288] s, aged 18 to 90 y ears. T he treatment duration was 5 to 15 day s (RECL AIM study ).  The 
doses administered were IV CAZ-AVI (500 mgavibactam and2000 mg ceftazidime), 
immediate lyfollowed by 500 mg I V metronida zole, or 1000 mg IV meropenem , and 
529patients in each treatment arm received study treatment.   Study  treatments were
administered ever
y8 hours. CAZ -AVI was non -inferior compared with meropenem. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00 015
Edition Number 2
Date 07 March 2017
19(88)CAZ-A
VIplus metronida zolewas effective intreatinginfections duetoGram-nega tive 
pathogens resistant toceftazidime with response rates similar tothatseen with cefta zidime -
susceptible isolates.  The adverse events (AEs) were generally  mild or moderate in severity  and 
the overa llfrequ ency and pattern of AEs w ere co mparable betweenthetreatment groups. 
Analy sis of the safety  topi[INVESTIGATOR_336289].
Another Phase [ADDRESS_415465] Available Therap y (BAT) for the treatment of infections due to ceftazidim e-resistant 
Gram-negative pathogens, which was conducted in 333 adults aged 18 to 90 y ears diagnosed 
with c IAI or cUTI.  The dose administered was 2000 mg ceftazidime/[ADDRESS_415466] of Cure (TOC) visit, the estimated clinical cure 
rate at the T OC visit was 90.9% for CA Z-AVIand 91.2% for BAT. InthemMITTanalysis
set,theper-patient favourable microbiological response rate forpatients with cUTI at the TOC 
visit was higher in the CAZ- AVI group than in the BAT group 
(81.9% versus 64.2% , 
respectivel y). 
There were no definitive conclusions of an ytreatment -related trends in patients with cIAI, 
and there were no obvious safe ty concerns identified from the data available. In the patients 
with cUTI, the proportion who experienced an AE up to the Late Follow -up ( LFU) visit was 
28.3% in the CAZ -AVI group and 35.3% in the BAT group.  For patients with cUTI and cIAI, 
themajority of AEs were mild or moderate in int ensity. Up to the LFU visit, the i ncidence of 
serious adverse events ( SAEs )was low and balanced across treatment groups (5.5% in the 
CAZ-AVI group and 6.0% in the BAT group).  All SAEs were assessed as not causally
related to the study treatment by[CONTACT_12244] r. The number of patients with AEs of special 
interest (AEoSI) wasgeneral lylow and balanced across treatment groups, with the exception 
of diarrhoea in patients with cUTI, which was higher in the BAT group (5.9% and 2.0%, for 
BAT and CA Z-AVI, respective ly).  No new safet yconcerns were identified from the safety
topi[INVESTIGATOR_23254]. Thefrequenc y ofpotentiall
yclinical ly significant changes in clinical 
laboratory tests wa salso low and balanced across treatment groups. There were no Hy 's Law 
cases.
A Phase 2 study  (NXL104/2001) examining the safety  of CAZ -AVI versus imipenem 
cilastatin followed b y appropriate oral therap y as a comparator was conducted in 137 patients 
aged 18 to 90 years with cUTIs.  In this study patients were randomised 1:1 and given 500 mg 
ceftazidime and 125 mg avibactam IV every  8hours or 500 mg imipenem cilastatin IV every  
6 hours.  Approximately  35% of patients in the CAZ -AVI group and 42% of patients in the 
imipenem cilastin group experienced a local reaction at the IV infusion site.   The majority  of 
the infusion site reactions were mild or moderate in intensity .  One patient in the imipenem 
cilastatin group experienced a severe local reaction (induration, swelling).  The most common 
infusion- related events across the treatment arms w ere ery thema, pain and tenderness.  Of 
note, patients in the CAZ- AVI group received 3 infusions per day , while patients in the 
imipenem cilastatin group received 4 infusions per day .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
20(88)In the Phase 2 stud y (NXL104/2002) examining CAZ -AVI plus metronidazole v ersus 
meropenem as a comparator in patients with cIAIs, approximately  30% of participants in both 
the CAZ -AVI and meropenem comparator treatment groups experienced at least [ADDRESS_415467] frequently  
across both groups.  The majority  of infusion site events were mild.  There was a somewhat 
greater percentage of patients with infusion site events of moderate/severe intensity  in the 
CAZ -AVI group, who also received IV metronidazole (17/101 patients [16.8%]) versus the 
meropenem group (11/102 patients [10.8%]).  Of note, patients in the CAZ- AVI plus 
metronidazole group received an infusion of [ADDRESS_415468] patients in the 
meropenem group received an infusion with
1study  drug per dose.
A Phase 1, open -label, single- dosestudyto characterise the pharmacokinetics (PK)of
CAZ
-AVI and assess its safe ty and tolerability  following a single IV dose was conducted in 
hospi[INVESTIGATOR_336290] 3 months to <18 years, receiving systemic antibiotic 
therap yfor suspected or confirmed infection. The patients in this study  were stratified by [CONTACT_336335]: Cohort 1, patients aged â‰¥12 to 
<18years; Cohort 2, patients aged â‰¥6 to <12years; Cohort 3, patients aged â‰¥2 to <6 years; 
and Cohort 4, patients aged â‰¥3 months to <2 years (split into [ADDRESS_415469] 4 patients 
each, â‰¥3months to <1 year and â‰¥1year to <2 years).  
Patients in Cohort 1 and any patients in Cohort 2 we ighing â‰¥40 kg received a single IV dose of 
CAZ-AVI (2000 m g ceftazidime and 500 mg avibactam) administered as a single infusion 
over a 2-hour period onDay 1.  Patients in Cohort 2 weighing <40 kg received a single IV 
dose of C AZ-AVI(50 m
g/kg ceftazidime and 12.5 mg/kg avibactam) administered as a single 
infusion over a 2 -hour period onDay 1.  These doses were applicable for patients with normal 
renal function and mild renal insufficiency (creatinine clearance [CrCl] >50 to â‰¤80 mL /min).
In Cohorts 3 and 4, patients with normal renal function or mild renal insufficiency  received a 
single IV dose of CAZ- AVI (50 mg/kg ceftazidime and 12.5 mg/kg avibactam) on Day  1. 
Each patient in the stud y received a single IV dose of CAZ-AVI administered as a continuous 
infusion over a 2- hour period.  There were [ADDRESS_415470] that the plasma ceftazidime and avibactam 
concentration profiles were similar in all 4 co horts across sampling time points.  
Review of the haematology , coagulation, clinical chemistry , and urinal ysis laboratory  values 
did not reveal an y unexpected findings within patients or an y trends across patients; there 
were no potentiall y clinically sig nificant haematology , clinical chemistry , or liver function test 
values reported.  No patients met Potential Hy â€™s Law criteria.  Review of vital signs values 
and phy sical examination findings did not identify  any new safet y concerns.  There were no 
clinica lly significant changes in electrocardiograms (ECGs) reported.  The single IV dose of 
CAZ -AVI was well tolerated, with no new safet y concerns identified in hospi[INVESTIGATOR_336291].
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
21(88)The risk considerations for this study  encompass the known and pot ential risks for CAZ- AVI 
and its component products avibactam and ceftazidime, as well as those risks associated with 
other treatments that may be administered as described in this protocol.  Other possible 
treatments include the marketed products metronid azole and meropenem.  As the risks for 
these marketed products are widel y available in their respective prescribing information, these 
risks will not be discussed within this section.
The risks for CAZ- AVI have not been fully  elucidated; however it is assu med that known or 
potential risks for CAZ -AVI should include those identified in the clinical studies with 
CAZ -
AVI, avibactam alone, and also for ceftazidime alone.  Additional risk information for 
avibactam and CAZ -AVI is located in the CAZ- AVI Investigat orâ€™s Brochure.
The full risk profile for ceftazidime is described in the prescribing information for the product 
(refer to local ceftazidime product labelling).  Important risks as laid out in the warnings and 
precautions in product labelling for ceftazidi me include:
ï‚·Hypersensitivity  reactions.  Though patients with hy persensitivity  and serious allergic 
reactions to cephalosporins, carbapenem or other Î² -lactam antibiotics are excluded 
from the trial, first -time epi[INVESTIGATOR_336292].
ï‚·Antibi otic-associated diarrhoea, Clostridium difficile diarrhoea, colitis, and 
pseudomembranous colitis
ï‚·Bacterial overgrowth with non- susceptible organisms
ï‚·Distal necrosis as a result of inadvertent intra -arterial administration of ceftazidime
ï‚·Elevated levels of ceftazidime used in patients with renal impairment have been 
associated with neurological sequelae such as tremors, my oclonus, seizures, 
encephalopath y, and coma
Potential risks for CAZ-AVI include the occurrence of events seen with ceftazidime alone, but
that go bey ond the frequency and/or severity  of those seen with ceftazidime.  L ocal 
intolerance has been seen in the preclinical studies, and has been monitored in the clinical 
programme.  In the Phase [ADDRESS_415471] al so been reported.  
In summary , the known and potential risks of receiving the developmental antibiotic 
combination CAZ -AVI are expected to be similar to those seen with ceftazidime and 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
22(88)cephalosporins in general.  Thus far, no unique risks have been identi fied for the avibactam 
component or the combination of CAZ-AVI.  The risks of the marketed antibiotics are 
considered acceptable.  Whilst it is anticipated that CAZ -AVI will have similar efficacy  for 
the treatment of cIAIs, it is possible that efficacy  will not be demonstrated.  For each patient in 
the trial, appropriate treatment of the cIAI is thus determined b y the clinical Investigator based 
on the clinical response of the patient.
1.4 Study design 
This study  will be a single blind, randomised, multi
-centr e, active controlled trial.  Patients 
aged from 3 months to less than 18 y ears with cIAI swill be randomised to 1 of 2 treatment 
groups (3:1 ratio): CAZ -AVI in combination with metronidazole versus meropenem.  Patients 
aged from 3 months to <1 year (Cohort 4b) must have been born at term (defined as 
gestational age â‰¥37weeks).
A sufficient number of patients are to be randomised 3:[ADDRESS_415472] 
72hours (3 full day s, ie, 9 doses) of study  treatment (ie, evaluable patients; at least [ADDRESS_415473] 20 patients in the meropenem group).
Patients will be allocated to 1 of 4 cohorts based on age.  R andomisation will be stratified as 
follows: 
ï‚·Cohort 1: At least 15:5 evaluable patients aged from 12 y ears to < 18 years
ï‚·Cohort 2: At least 15:5 evaluable patients aged from 6 y ears to <12 years
ï‚·Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 y ears
ï‚·Cohort 4: 
No required minimum of evaluable patients aged from 3 months to <2 years, 
compris ing Cohorts 4a and 4b as follows:
ï€­Cohort 4a: P atients aged from 1 year to <2 years
ï€­Cohort 4b: Patients aged from 3 months to <1 year
Intravenous CAZ- AVI infusions will be given at doses based on age and weight 
with 
adjustment according to renal function as detailed in Table 5.
Patients whose CrCL  drops below 30 mL /min should be withdrawn from study  therapy .  
Patients withdrawing from study  therap y can b e administered alternative therapi[INVESTIGATOR_336281]â€™s choice, which should be recorded in the Case Report Form (CRF).  If possible, 
patients should still be followed for safet y (see Section 3.9.1).  Because the CrCl 
determination is only  an estimate of renal function, in instances where the CrCl is approaching 
thresholds that would require intervention such as a dose change or discont inuation of therapy  
(ie CrCL  approaching 50 or 30 mL /min) , the Investigator should use his or her discretion in 
determining (ie confirming the value b y repeat testing, if feasible) whether an immediate dose 
change, a short period of continued observation, or discontinuation of therapy  is warranted. If 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
23(88)in the opi[INVESTIGATOR_2511] I nvestigator there is a clinically  significant reduction in a patientâ€™s 
estimated CrCl during the treatment period, then the Investigator should contact [CONTACT_336336] (immediate dose change, a short period of 
continued observation, or discontinuation of therapy ). Additionally , in instances of rapi[INVESTIGATOR_2478] y 
changing renal function, the I nvestigator should increase the frequency  of CrCl monitoring, 
depending on the patientâ€™s clinical status, extent of renal function change and I nvestigatorâ€™s 
clinical evaluation.
The suggested dosing regimen of m etronidazole is10mg/kg IV over 20 to 30 minutes 
every  
8hours (Â±30 minutes) , but it can also be prescribed/ adjusted by  [CONTACT_336325].  The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ -AVI infusion. The dose/regimen of meropenem will be 20 mg/kg 
every  8hours (Â±1 hour) infused over approximately  15 to 30 minutes or up to 1 hour (or 
infusion duration as per local guidelines).  For patients weighing over 50 kg, the maximum 
dose of meropenem should not exceed 1 g every  8 hours.  
Patients will receive IV treatment for a minimum of 72 hours (3 full day s, ie, 9 doses) before 
having the option to switch to an oral therap y, as specified in 
Section 7.7below.  The decision 
to switch to oral therap y is entirely  at the Investigatorâ€™s discretion, if the patient has good or 
sufficient clinical response, and the patient is tolerating oral fluids or food.   The total period of 
treatment ( ie, IV drug and oral switch treatment) is to be between 7 and 15 day s.  Patients may  
remain on the IV stud y treatment for the full 7 to 15 days.
Patients will be assessed for safety  and efficacy  throughout the study , and blood samples will 
be taken for PK assessment.  The duration of each patientâ€™s participation in the study  will be a 
minimum of [ADDRESS_415474] 
dose of an y treatment.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
24(88)Figure 1 Study flow chart
ï‚·
ï‚·
ï‚·
ï‚·
ï‚·
ï‚·Patients with cIAIRandomisation 
(3:1) to CAZ -AVI 
plus metronidazole 
or meropenem* 
treatmentCAZ -AVI 
infused over 
2hours, then 
metronidazole*
infused over 20 
to 30 min utes
Meropenem* 
20mg/kg 
infused over 
approx. 15 to 
30minutes or up 
to 1 hour **End of IV 
drug or oral 
switch 
therapy
visit***Test of Cure
visit
[ADDRESS_415475] 
dose of 
study drug 
(IV or oral)Last Follow -up 
visit
27 to 50 days 
after start of 
study treatment
Screening Treatment Follow Up
*Optional switch to oral therapy permitted on or after Study Day 4 (ie, after 72 hours [3 full days, ie, 9 doses] of IV study drug .  Assessment should be 
performed no later than 8 hours after the 72 -hour time point .  The decision to sw itch to oral therapy is entirely at the Investigatorâ€™s discretion, if the 
patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food :
-Oral amoxicillin/clavulanic acid ( only in countries where its use for children is permitted; according to local guidelines, administered at a dose and 
formulation per standard of care), or
-Oral ciprofloxacin ( only in countries where its use for children is permitted; according to local guidelines, administered at a dose and formulation per 
standard of care) plus metronidazole (administered at a dose an d formulation per standard of care), or
-Pathogen -based therapy (in discussion with the Medical Monitor) , see Section 7.7.
The patient may continue on IV study drug for the entire duration of the study therapy (7 to 15 days), at the discretion of the Investigator.
** Or infusion duration as per local guidelines.  For patients weighing over 50 kg, the maximum dose of meropenem should not exceed 1 g every 
8hours.  
*** Visit performed within [ADDRESS_415476] dose of oral switch therapy.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
25(88)2. STUDY OBJECTIVES
2.1 Primary objective (safety)
Primary Objective: Outcome Measure:
Evaluate the safety and tolerability of 
CAZ -AVI plus metronidazole given at the 
selected dose regimen versus meropenem in 
paediatric patients aged â‰¥3months to 
<18years with cIAIï‚·AEs and SAEs from the signing of the Informed 
Consent Form (ICF)/Assent Form to the LFU 
visit (27 t o 50 days after start of study treatment)
ï‚·Cephalosporin class effects and additional AEs 
(including, but not limited to seizures, 
C.difficile -associated diarrhoea, allergic 
reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function)
ï‚·Clinical: vital signs (pulse, blood pressure, 
respi[INVESTIGATOR_697], temperature), ECG, and physical 
examinations
ï‚·Laboratory: complete blood count with 
differential and comprehensive metabolic panel
ï‚·CrCl 
2.2 Secondary objectives
Secondary Objective: Outcome Measure:
Evaluate the descriptive efficacy of CAZ -AVI 
plus metronidazole versus meropenem in 
paediatric patients aged â‰¥3 months to 
<18years with cIAIï‚·Clinical outcomes at End of 72 hoursâ€™ Treatment, 
End of Intravenous Treatment (EOIV), End of 
Treatment (EOT), and TOC
ï‚·Microbiological response at EOIV, EOT, TOC 
and LFU
ï‚·Clinical relapse at LFU
ï‚·Emergent infections
Evaluate the PK of CAZ -AVI in paediatric 
patients aged â‰¥3months to <18 years with 
cIAIï‚·PK data of ceftazidime and avibactam will be 
analy sed separately
ï‚·Plasma concentration will be listed and 
summarised by [CONTACT_336323]
ï‚·PK parameters derived from population PK 
analysis and potential PK/PD relationships will 
be reported separately
2.3 Safety objectives 
Safety  is the primary  objective.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
26(88)2.[ADDRESS_415477] AWAL 
Each patient should meet all of the inclusion criteria and none of the exclusion criteria for this 
study .  Under no circumstances can there be exceptions to this rule.
3.1 Inclusion criteria
For inclusion in the study patients should fulfil the following criteria:
1. Must be â‰¥3 calendar months to <18 y ears of age.  Patients aged 
â‰¥3 calendar months 
to <[ADDRESS_415478] been born at term (defined as gestational age â‰¥37 weeks).
2. Written informed consent from parent(s) or other legally
 acceptable 
representative(s), and informed assent from patient (if age appropriate according to 
local regulations)
3. If female and has reached menarche, or has reached Tanner stage 3 development 
(even if not having reached menarche) (refer to Appendix E for further details on 
Tanner staging), the patient is authorised to participate in this clinical study if the 
following criteria are met:
At screening:
(i) (a) Patient reports sexual abstinence for the prior [ADDRESS_415479] 
1 of the acceptable methods of contraception, including an intrauterine device (with 
copper banded coil), levonorgestrel intrauterine s ystem (eg, MirenaÂ®), or regular 
medrox yprogesterone injections (Depo -ProveraÂ®); or (b) Patient agrees to initiate 
sexual abstinence from the time of screening until 7 days after end of treatment with 
study  drug; and
(ii) Patient is advised to avoid conception from the time of screening until 7 day s after 
receipt of stud y drug and agrees not to attempt pregnancy  from the time of 
screening until 7 day s after end of treatment with study  drug; and
(iii) Patient is provided guidelines regarding continuation o f abstinence, initiation of 
abstinence, or about allowed contraception; and
(iv) Patient has a negative serum Î² -human chorionic gonadotropin (Î² -hCG) test just 
prior to study  entry .  Since serum tests may  miss an earl y pregnancy, relevant 
menstrual history  and sexual history , including methods of contraception, should be 
considered.  Note: if the result of the serum Î² -hCG test cannot be obtained prior to 
dosing of investigational product, a patient may  be enrolled on the basis of a 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
27(88)negative urine pregnancy test, though a serum Î²- hCG test result must still be 
obtained.
Note 1: Hormonal contraceptives delivered orally, as patches, or via vaginal devices should 
not be used as a method of birth control because the effect of CAZ -
AVI on the efficacy of these 
types of co ntraceptives has not yet been established.  
Note 2: Barrier methods (such as male condom) can be used as a means of preventing 
sexually transmitted disease but are not acceptable as a means of contraception for this 
clinical trial.  
4. Must, based on the ju dgment of the Investigator, require hospi[INVESTIGATOR_336293] y for 7 to 15 day s in addition to surgical intervention for the 
treatment of the current cIAI
5. Require surgical intervention (eg, laparotom y, laparoscopic surgery or percu taneous 
drainage) to manage the cIAI 
6. Must have clinical evidence of cIAI as follows:
(i) Pre-operative enrolment inclusion:
(a)Requires surgical intervention that is expected to be completed within 24 hours 
of enrolment
ï€­Laparotom y, laparoscop y, or percutaneous drainage 
(b)Evidence of a s ystemic inflammatory  response (at least 1):
ï€­Fever (defined as oral temperature >38.5Â°C, or equivalent to method used) or 
hypothermia (with a core body  or rectal temperature <35Â°C, or equivalent to 
method used)
ï€­Elevated white blood cells (WBC) (>[ZIP_CODE] cells/mm3)
ï€­C-reactive protein (CRP) levels (>10 mg/L )
(c)Physical Findings consistent with intra -abdominal infection, such as:
ï€­Abdominal pain and/or tenderness
ï€­Localised or diffuse abdominal wall rigidity
ï€­Abdominal mass
(d)Intention to send specimens from the surgical intervention for culture
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Cefta zidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
28(88)(e)(Optional) Supportive radiologic findings of intra -abdominal infection, such as 
perforated intraperitoneal abscess detected on: 
ï€­Computed tomograph y (CT) scan or
ï€­Magnetic resonance imaging (MRI) or
ï€­Ultrasound
(ii) Intra -operative/postoperative enrolment inclusion (in cases of postoperative 
enrolment, must be within 24 hours after the time of incision
):
Visual confirmation of intra-abdominal infection associated with peritonitis at 
laparotomy , laparoscopy  or percutaneous drainage (to be confirmed pending 
feasibility ); must have 1 of these diagnoses:
(a)Appendiceal perforation or peri- appendiceal abscess
(b)Cholecy stitis with gangrenous rupture or perforation or progression of th e 
infection bey ond the gallbladder wall
(c)Acute gastric or duodenal perforations, onl y if operated on >24 hours after 
singular perforation occurs
(d)Traumatic perforation of the intestines, only  if operated on >12 hours after 
perforation occurs
(e)Secondary  perito nitis (but not spontaneous bacterial peritonitis associated with 
cirrhosis and chronic ascites)
3.2 Exclusion criteria
Patients should not enter the study  if an y of the following exclusion criteria are fulfilled:
1. Involvement in the planning and/or conduct of the study  (applies to both 
[COMPANY_008] staff and/or staff at the stud y site)
2. Previous enrolment or randomisation in the present study
3. Participation in another clinical study with an investigational product (I P) during 
the last [ADDRESS_415480] previousl y 
participated in the current study  or in another study  of CAZ -AVI (in which an 
active agent was received) 
4. History  of hypersensitivity  reactions to carbapenems, cephalosporins, penicillin, 
other Î² -lactam antibiotics ,metronidazole , or to nitroim idazole derivatives
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
29(88)5. Concurrent infection, that may  interfere with the evaluation of response to the study  
antibiotics at the time of randomisation
6. Patient needs effective concomitant sy stemic antibacterials (oral, IV, or 
intramuscu lar) in addition to those designated in the 2 study  groups (CAZ -AVI plus 
metronidazole group or meropenem group) (see Section 7.8)
7. Receipt of non -
study systemic antib acterial drug therapy  for cIAI , for a continuous 
duration of more than [ADDRESS_415481] dose of IV 
drug, except in proven resistant organisms and /or worsening of the clinical 
condition
.  More than 2 consec utive doses are not permitted if the individual
doses 
areexpected to give >12 hoursâ€™ cover (ie, giving a total cover of >24 hours. ) For 
patients enrolled after a surgical procedure, onl y 1 dose of non- study  antibiotics is 
permitted postoperatively . 
8. Patient is considered unlikely  to survive the 6 to 8 week study  period
9. Patient is unlikely to respond to 7 to 15 day s of treatment with antibiotics
10. Patient is receiving haemodialy sis or peritoneal dialy sis
11. Diagnosis of abdominal wall abscess confined to mu sculature of the abdominal wall 
or ischaemic bowel disease without perforation, traumatic bowel perforation 
requiring surgery  within 12 hours of perforation, or perforation of gastroduodenal 
ulcers requiring surgery  within 24 hours of perforation (these ar e considered 
situations of peritoneal soiling before the infection has become established)
12. Simple (uncomplicated), non- perforated appendicitis or gangrenous appendicitis 
without rupture into the peritoneal cavity  identified during a surgical procedure OR 
presence of primary  peritonitis (ie, spontaneous bacterial peritonitis) or peritonitis 
associated with cirrhosis or chronic ascites
13. At the time of randomisation, patient is known to have a cIAI caused b y pathogens 
resistant to the study  antimicrobials plann ed to be used in the study
14. Presence of an y of the following clinicall y significant laboratory abnormalities: 
(a) Haematocrit <25% or haemoglobin <8 g/dL (<80g/L, <4.9 mmol/L) 
(b) Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3Ã—the 
age-specific upper limit of normal (ULN), or total bilirubin >2Ã—ULN (except 
known Gilbertâ€™s disease)  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
30(88)For a) and b ): unless if these values are acute and directly  related to the infectious process 
being treated.  
15. Creatinine clearance <30mL/min/1.73 m2calculated using the childâ€™s measured 
height (length) and serum creatinine within the updated â€œbedsideâ€ Schwartz formula 
(Schwartz et al 2009 ): 
CrCl (mL /min/1.73m2)=0.413Ã—height (length) (cm)/serum creatinine (mg/dL)
16. History  of seizures, excluding well- documented febrile seizure of childhood
17. Any situation or condition that would make the patient, in the opi[INVESTIGATOR_684], unsuitable for the study  (eg, would place a patient at risk or 
compromise the quality  of the data) or may  interfere with optimal participation in 
the study
18. If female, currentl y pregnant or breast feeding
See 
Section 3.4for procedures for withdrawal of incorrectly  enrolled patients.
3.[ADDRESS_415482] enrolment and randomisation
Investigator(s) should keep a record, the patient screening log, of patients who entered 
pre-study  screening.  Patients will be enrolled if they  meet all the inclusion criteria, including 
informed consent and assent in writing from parent(s) or other legally -acceptable 
representative(s)/patient as applicable, and none of the exclusion criteria.  T he Blinded 
Observer may  perform screening and enrolment; however, the Investigator must perform 
randomisation. 
The Blinded Observer/Investigator will:
1. Obtain signed informed consent from the parent or guardian/legall y acceptable 
representative(s) of the p otential patient and informed assent from the potential 
patient (if age appropriate according to local regulations) before an y stud y specific 
procedures are performed
2. Assign potential patient a unique enrolment number, beginning with â€˜E#â€™
3. Determine patient eligibility  (see Sections 
3.1and 3.2)
4. Investigator only : Assign eligible patient unique randomisation code (via an 
interactive voice/web response sy stem [IXRS] not available for access by  [CONTACT_336337])
If a patient withdraws from participation in the study , then his/her enrolment/rando misation 
code cannot be reused.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Proto col
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
31(88)Randomisation codes will be assigned strictly  sequentially  as patients become eligible for 
randomisation.
3.[ADDRESS_415483] ensure all decisions are appropriately  documented.
3.5 Methods for assigning treatme nt groups
Block randomisation using an IXRS will be used to assign patients in a ratio of 3:1 to the 
study  treatment groups of CAZ -AVI plus metronidazole or meropenem, respectively , in each 
of the cohorts for the age groups (see Section 8.2for a description of the sample size).
A representative of [COMPANY_008], under the supervision of [COMPANY_008] statistical personnel, 
will perform this randomisation .  
3.[ADDRESS_415484] 1 blinded Investigator (referred to as â€œBlinded Observerâ€
hereafter) will not know the patientâ€™s treatment a ssignment and will conduct clinical 
assessments related to safety and efficacy .  The Blinded Observer may  perform screening and 
enrolment activities but will not be responsible for randomising patients (the Blinded 
Observer will not have access to the IXRS ).  The Blinded Observer will not ask other 
members of the study team, the patient, or the patientâ€™s parent(s)/legall y acceptable 
representative(s) which study  treatment is being given, and will avoid all attempts to uncover 
treatment assignment.  The Blin ded Observer should arrange to see the patient during times 
when study  drug is NOT being administered, and not when assessments are being performed 
that could possibly  unblind the Blinded Observer, in order to maintain the blind.  I f possible, 
the same Bli nded Observer should complete all clinical assessments for a patient. The 
Blinded Observer should perform all causalit y assessments for all AEs and SAEs. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
32(88)At each investigational site, an unblinded Investigator (referred to as â€œInvestigatorâ€ hereafter), 
Pharmacist or designee, study  centre personnel, patient, and parent(s)/legally acceptable 
representative(s) may  be aware of which IV stud y drug therap y is being administered and 
shall be instructed not to reveal to the Blinded Observer which drug the patien t is receiving. 
Refer to Section 3.7if the Blinded Observer learns of the treatment assignment. 
3.7 Methods for unblinding 
Individual treatment codes , indicating the treatment randomisation for each randomised 
patient, will be available to the I nvestigator(s) or pharmacists from the IXRS.  Routines for 
this will be described in the IXRS user manual that will be provided to each centre.
This study  has a n observer -blinded design.  During the stud y, the Blinded Observer(s) will not 
make an y effort to determine which IV stud y drug is being administered.  The details of 
blinding will be described in the Blinding Plan.
Only  in the case of an emergency , when knowledge of the study  drug is essential for the 
immediate clinical management or welfare of a specific patient andthe Investigator or 
designee is not available to provide or cannot provide appropriate medical care t o the patient, 
may the Blinded Observer be unblinded to the patientâ€™s treatment assignment.
Before an y unblinding of the Blinded Observer, it is strongl y advised to discuss options with 
the Medical Monitor or appropriate stud y personnel.  As soon as possib le, and without 
revealing the patientâ€™s study  treatment assignment (unless important to the safet y of patients 
remaining in the stud y), the Blinded Observer or designee must notify PRA if the observer 
blind is broken for any reason and the Blinded Observer was unable to contact [CONTACT_336338].  PRA will inform [COMPANY_008] of the incident .
3.[ADDRESS_415485] to drug -to-drug interaction, such as 
pi[INVESTIGATOR_3353], patches, and intravaginal devices, are not acceptable methods of birth control during this 
study  based on potential for antibiotics to alter gut flora, hormone absorption, and hormone 
effectiveness.  If an adolescent female stud y participant was previously using hormonal 
contraceptives such as pi[INVESTIGATOR_3353], patches , and intravaginal devices, she should follow her health 
care providerâ€™s specific recommendations for effective use of these methods after completing 
IV study  therapy .  Such recommendations may  address the need for a second method of 
contraception until th e hormonal method becomes fully  effective.
3.[ADDRESS_415486]
Patients may  be discontinued from IP in the following situations:
ï‚·Patient or patientâ€™s parent(s)/legally  acceptable representative(s) decision.  The patient 
or the patientâ€™s parent(s) or other legall y acceptable representative(s) is at any time 
free to decide to discontinue treatment, without prejudice to further treatment
ï‚·AE (eg, risk to patients, as judged b y the Investigator)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
33(88)ï‚·Positive pregnancy  test at any  time during t he study  treatment period
ï‚·In the absence of an y alternative explanation for an increase in the following 
abnormalities, individual patients should be withdrawn if the following hepatic/liver 
criteria are met:
ï€­ALT or AST >8Ã—ULN
ï€­ALT or AST â‰¥3Ã—ULN and either total bilirubin â‰¥2Ã—ULN or evidence of 
coagulopath y.  Evidence of coagulopath y should be discussed with the PRA 
physician where possible
ï€­ALT or AST â‰¥3Ã—ULN and with appearance of s ymptoms suggestive of new or 
progressive liver disease.  Sy mptoms suggestive o f new or progressive liver 
disease should be discussed with the PRA phy sician where possible
ï‚·Significant 
reduction in CrCl measurements as judged b y the Investigator
ï‚·CrCl value <30mL/min
ï‚·Severe non -compliance with study  protocol, as judged b y the Investigator
ï‚·In the opi[INVESTIGATOR_689], it is not in the best interest of the patient to continue 
study  therapy  and/or lack of efficacy
3.9.[ADDRESS_415487] 
At any  time, patients or the patientâ€™ s parent(s) or other legall y acceptable representative(s) are 
free to decide to discontinue the childâ€™s use of IP or withdraw from the study  (ie, IP and 
assessments â€“ see Section 3.10), without prejudice to further treatment.  A patient or the 
patientâ€™s parent(s) or other legall y acceptable representative(s) who decides to discontinue I P 
will alway s be asked about the reason(s) and the presence of an y AEs.  If possible, they  will 
be seen and assessed b y an Investigator(s).  
Adverse events and SAEs will be followed up (See Section 6).  For pati ents who discontinue 
IP earl y, their follow -up assessments should be collected (see Section 6.3.2 for follow -up of 
unresolved AEs).  Liver CRF modules should be completed for patients discontinued after 
meeting hepatic/liver criteria.  The patient should be scheduled for the EOIV visit within 
24hours after IV stud y therap y discontinuation, ideally  before starting any new antibiotic 
treatment.
If a p atient is withdrawn from study , see 
Section 3.10.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
34(88)3.[ADDRESS_415488] provided informed consent/assent and subsequently  who 
do not fulfil the eligibility  criteria for the study , and therefore must not be randomised.  These 
patients should have the reason for stud y withdrawal recorded as â€˜Failed Eligibility  Criteriaâ€™ 
(ie, patient does not meet the required inclusion/exclusion criteria).  This reason for stud y 
withdrawal is only  valid for screen failures (not randomised patients).
3.10.2 Withdrawal of the informed consent
Patients or the patientâ€™s parent(s) or other legally  acceptable representative(s) are free to 
withdraw the child from the study  at any  time (IP and assessments), without prejudice to 
further treatment.
A patient or the patientâ€™s parent(s) or other legally  acceptable representative (s) who withdraws 
consent will alway s be asked about the reason(s) and the presence of any  AEs.  The 
Investigator will follow up AEs outside of the clinical study. 
If a patient withdraws from participation in the study , then his/her enrolment/randomisatio n 
code cannot be reused. 
3.11 Discontinuation of the study
The study  may  be stopped if, in the judgment of [COMPANY_008], trial patients are placed at 
undue risk because of clinically  significant findings that:
ï‚·Meet individual stoppi[INVESTIGATOR_336294] 
ï‚·Are assessed as causall y related to stud y drug 
ï‚·Are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the patients at the time of 
discontinuation of follo w-up must be recorded in the CRF.  All reasons for discontinuation of 
treatment must be documented.
In terminating the study , the Sponsor will ensure that adequate consideration is given to the 
protection of the patientsâ€™ interests.
4. STUDY PLAN AND TIMIN G OF PROCEDURES 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
35(88)Table 1 Study plan detailing study procedures
Assessment or Procedure Baseline1Treatment Follow -up
Day 12Days
2 and 3Days
4 to â‰¤153EOIV4EOT5
(Oral 
only)TOC6LFU7
ICF (and Assent Form, if applicable)8X
Verify inclusion/exclusion criteria XClinicalMedical and surgical history X
Complete physical examination9XX After 72 hoursâ€™ 
treatment onlyX X X X10
Prior and concomitant medications 
(including lactating mother)[ADDRESS_415489] adjunctive therapeutic 
procedures (if performed)X X X X X X X
Record radiological examinations14X
Clinical outcomeX15After 72 hoursâ€™ 
treatment onlyX15X15X15X16
AEs and SAEs17X X X X X X X XLaboratoryComplete blood count with 
differential, chemistry panel, CrCl 
calculation, ESR, and optional CRP 18XIf clinically 
indicatedX19X20If 
clinically 
indicatedX21If 
clinically 
indicated
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
36(88)Assessment or Procedure Baseline1Treatment Follow -up
Day 12Days
2 and 3Days
4 to â‰¤153EOIV4EOT5
(Oral 
only)TOC6LFU7
Urine or serum pregnancy test22X X
Urine sample routine analysis23X If clinically indicatedMicroIntra -abdominal fluid sample24X If clinically indicated
Blood sample for culture25Blood cultures should be performed as clinically indicated.PKBlood for PK analyses26X
Randomisation27X
Study drug administration X X X X
Oral switch therapy administration 
(optional at Investigatorâ€™s discretion)X
ESR=erythrocyte sedimentation rate
1.Perform baseline assessments within [ADDRESS_415490] day of IV study drug administration; subsequent study days are consecutive days.  Perform Day [ADDRESS_415491] 1 dose of IV study drug.
3.On Days 4 to â‰¤15, study drug administration applies to all patients and daily assessments are to be performed only for patients on IV study drug.
4.Perform EOIV assessments in person by [CONTACT_336339] w ithin [ADDRESS_415492] infusion of s tudy drug or at time of premature 
discontinuation of study drug or early withdrawal from study (if on IV study drug).  Conduct the EOIV assessments in place of the regular study visit (eg, 
Days 4 to â‰¤15) assessments that w ould have been performed the day o f that visit.  A patient may be eligible to switch to oral therapy on or after Day 4 
(Section 7.2); EOIV assessments must occur before starting oral sw itch therapy.
5.Perform EOT assessments in person w ithin [ADDRESS_415493] dose of oral switch therapy or at time of premature disconti nuation of study drug or 
early withdraw al from study (if on oral switch therapy). 
6.Perform TOC assessments in per son [ADDRESS_415494] dose of any study drug (IV or oral).
7.Perform LFU assessments [ADDRESS_415495] dose of any study drug (IV or oral).  Conduct LFU via telephone for any pati ent who has not 
experienced clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop AEs or SAEs since TOC. If symptoms of relapse or new AEs 
or SAEs are noted, or at the discretion of the Blinded Observer or Investigator, the patient should be immediately scheduled for an in -person visit.
8.Obtain informed consent from parent(s) (or other legally acceptable representative[s]) in writing and informed assent from patient (if age appropriate 
according to local requirements) before initiating any study assessments or procedures.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
37(88)9.Height measured at Baseline only.  Weight measured at Baseline only ,but should be measured at subsequent time points if clinically indicated and 
feasible .  Physical examination to be performed after completion of 72 hoursâ€™ treatment (either Day 3 or Day 4, depending on t iming of treatment 
administration).   Assessment should be performed no later than [ADDRESS_415496] dose of study therapy until LFU 
will also be recorded.
12.Temperature, respi[INVESTIGATOR_697], pulse and blood pressure, by [CONTACT_336340]â€™s age.  To be performed be fore ECG on days when both 
assessments ar e indicated. 
13.Baseline ECG to be performed prior to obtaining blood samples for laboratory testing.  Day [ADDRESS_415497] scans, ultrasound and/or MRI scans with or without contrast.
15.Blinded Observer : Assess clinical outcome per protocol, assessment after 72 hours of treatment . Assessment shou ld be performed no later than 8 hours 
after the 72 -hour time point (no assessment required on Day 2).
16.Blinded Observer: Assess patients for clinical relapse per protocol.  Emergent infections will be assessed up to LFU.
17.Investigator or Blinded O bserver : Collect and report AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days after 
any dose of study drug (IV or oral) (or LFU, whichever is later); site staff are to follow unresolved AEs and SAEs at LFU unt il resolution or stabilisation.  
The causality assessment should be done by [CONTACT_336339] (not the Investigator) for all AEs and SAEs.
18.Laboratory tests indicated at Baseline do not need to be repeated if they were performed within [ADDRESS_415498] of care. C -reactive protein and 
CrCl calculation may be repeated at additional time points if clinically indicated.  Additionally, in instances of rapi[INVESTIGATOR_336295], the 
Investigato r should increase the frequency of CrCl monitoring, depending on the patientâ€™s clinical status, extent of renal function change and the 
Investigatorâ€™s clinical evaluation . Direct Coombs test at Baseline and TOC only.  Test results of any samples taken as s tandard of care should be recorded 
in the CRF. 
19.Conduct on Day 7 if patient is still on IV study drug at that time.
20.If EOIV occurs within 48 hours after these assessments are performed on Study Day 7, do not repeat these assessments.
21.Perform at TOC only if patient had an abnormal (high/low flag) result on or after EOIV.
22.Perform test if patient is a female who has reached menarche or has reached Tanner stage 3 development (even if not having re ached m enarche).  If a 
pregnancy test is positive post baseline, follow reporting requirements in Section 6.6.  Note: if the result of the serum Î² -hCG test cannot be obtained prior 
to dosing of investigational pro duct, a patient may be enrolled on the basis of a negative urine pregnancy test, though a serum Î² -hCG test result must still 
be obtained.  At TOC, a serum pregnancy test is required.  
23.At Baseline, before any antibiotics are administered. Subsequent additi onal time points if clinically indicated.
24.At Baseline , make every attempt to obtain intra -abdom inal fluid sample preferably before any antibiotics administered .Subsequent time points if 
clinically indicated.
25.If clinically indicated and not already collect ed per standard of care .  
26.Blood samples for PK (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3 , 4a, and 4b ) will be collected from patients 
randomised to CAZ -AVI plus metronidazole treatment on Day 3 following a dose administrati on that is convenient for the plasma sample collections at 
the following time points: anytime within 15 minutes prior to or after stoppi[INVESTIGATOR_336296] -AVI infusion, anytime between 30 minutes and 90 minutes after 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
38(88)stoppi[INVESTIGATOR_336296] -AVI infusion, and anytime betw een 300 minutes (5 hours) and 360 minutes (6 hours) after stoppi[INVESTIGATOR_336296] -AVI infusion.  Every attempt 
should be made to obtain at least 1 sample from each of the 3 time windows for each patient.  Blood samples should be taken i n a manner such that the 
Blinded Observ er rem ains blinded.
27.Verify that the patient meets all study inclusion and no exclusion criteria before randomisation.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
39(88)4.1 Enrolment/screening period
Procedures will be performed according to the Study Plan ( Table 1).  D etails of study  
assessments are provided in 
Section 5.
At screening, consenting/assenting patients will be assessed to ensure that they meet eligibility  
criteria.  Patients who do not meet these criteria must not be enrolled in the study .  Basel
ine 
assessments must be performed within [ADDRESS_415499] dose of IV study  
drug.  The following assessments will be performed at Baseline: 
ï‚·Provision of informed consent/assent and verification of inclusion and exclusion 
criteria.  I nformed consent should be obtained from the parent(s) (or other legally  
acceptable representative[s]) in writing and informed assent from the patient (if age 
appropriate according to local requirements) before initiating an y stud y assessments or 
procedures .
ï‚·Medical and surgical history
ï‚·Complete phy sical examination , including height and weight
ï‚·Prior and concomitant medication recording, including medications taken by  [CONTACT_336341].  Prior medications include all prescription and
over-the-counter medications being taken b y the patient (and lactating mother, if 
patient is breast fed) for the 2 weeks prior to study entry.
ï‚·Vital signs (temperature, respi[INVESTIGATOR_2842], pulse and blood pressure, by  [CONTACT_336342]â€™ s age).  To be performed before the ECG.
ï‚·ECG (to be performed prior to obtaining blood samples for laboratory  testing)
ï‚·Record radiologic examinations
ï‚·AEs and SAEs to be collected from the time of provision of informed consent/assent
ï‚·Complete blood count wi th differential, Direct Coombs test, 
chemistry  panel, ESR (if 
clinically  indicated or if required per standard of care), CrCl calculation, and optional 
CRP.  Note: Laboratory  tests indicated at Baseline do not need to be repeated if they  
were performed wit hin [ADDRESS_415500] of care .  
C-reactive protein and CrCl calculation may be repeated at additional time points if 
clinically  indicated. Additionally , in instances of rapi[INVESTIGATOR_336282], the 
Investigator should increase the frequency  of CrCl monitoring, depending on the 
patientâ€™s clinical status, extent of renal function change and the Investigatorâ€™s clinical 
evaluation .  Test results of any  samples taken as standard of care should be recorded in 
the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
40(88)ï‚·Urine or serum pregnancy  test applicable onl y to female patients who have reached 
menarche or have reached Tanner stage 3 development (even if not having reached 
menarch e).  If a pregnancy  test is positive post -baseline, follow reporting requirements 
in Section 6.6.  Note: if the result of the serum Î² -hCG test canno
t be obtained prior to 
dosing of IP, a patient may  be enrolled on the basis of a negative urine pregnancy  test, 
though a serum Î²- hCG test result must still be obtained.
ï‚·Urine sample for routine anal ysis 
ï‚·Intra -abdominal fluid sample collection (preferably  
before administration of any  
antibiotics)
ï‚·Blood sample for culture (if clinically  indicated and not already  collected per standard 
of care)
ï‚·Randomisation via I XRS only  after verification of all inclusion and exclusion criteria
4.2 Treatment period
The procedures for this period are listed in the Study Plan ( Table 1).  D etails of study  
assessments are provided in 
Section 5.
4.2.[ADDRESS_415501] day  of IV study  drug administration; subsequent study  days are consecutive 
days.  Day  [ADDRESS_415502] 1 dose of IV 
study  drug.  The following will be performed: 
ï‚·IV study  drug administration: CAZ -
AVI plus metronidazole or meropenem; see 
Section 7.2for dosing and treatment regimens
ï‚·Recording of concomitant medications, including mother if patient is breast fed
ï‚·Vital signs (to be performed before the ECG)
ï‚·ECG within [ADDRESS_415503] study  treatment infusion
ï‚·Recording of an yadjunctive therapeutic procedures performed
ï‚·If clinicall y indicated: CrCl calculation, urine sample for routine anal ysis, 
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional) , weight (if feasible) . Additionally , in inst ances of rapi[INVESTIGATOR_336297], the Investigator should increase the frequency  of CrCl monitoring, depending 
on the patientâ€™s clinical status, extent of renal function change and the Investigatorâ€™s 
clinical evaluation .  
Test results of any  sample s taken as standard of care should be 
recorded in the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
41(88)ï‚·Recording of an y AEs/SAEs
4.2.2 Days 2 and 3
The following will be performed: 
ï‚·IV study  drug administration
ï‚·Complete phy sical examination after completion of 72 hoursâ€™ treatment only.  This 
assessment may  be performed on Day  4, depending on the timing of treatment 
administration.   Assessment should be performed no later than 8 hours after the 
72-hour time point.
ï‚·Recording of concomitant medications, including mother if patient is breast fed
ï‚·Vital signs 
ï‚·Recording of an y adjunctive therapeutic procedures performed
ï‚·Assessment of clinical outcome after 72 hoursâ€™ treatment . 
Assessment should be 
performed no later than 8 hours after the 72 -hour time point (assessment is not 
required on Day
2).  See Section [IP_ADDRESS] for definitions of clinical outcomes.
ï‚·Recording of an y AEs/SAEs
ï‚·If clinicall y indicated: CrCl calculation, urine sample for routine anal ysis,
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional) , weight (if feasible) . Additionally , in instances of rapi[INVESTIGATOR_336297], the Investigator should increase the frequency  of CrCl monitoring, depending 
on the patientâ€™s clinical status, extent of renal function change and the Investigatorâ€™s 
clinical evaluation .  Test results of any  samples taken as standard of care should be 
recorded in the CRF.
ï‚·Blood sampling for PK analy sis from patients randomised to CAZ -AVI plus 
metronidazole treatment on Day  3 only .  To be performed following a dose 
administration that is convenient for the plasma sample collections at the following 
time points: any time within 15 minutes prior to or after stoppi[INVESTIGATOR_336296] -AVI infusion, 
anytime between 30 minutes and 90 minutes after stoppi[INVESTIGATOR_336296] -AVI infusion, and 
anytime between 300 minutes (5 hours) and 360 minutes (6 hours) after stoppi[INVESTIGATOR_336298] -AVI infusion.  Every  attempt should be made to obtain at least 1 sample from 
each of the 3 time win dows for each patient.
4.2.3 Days 4 to â‰¤15
On Day s 4 to 
â‰¤15, study  drug administration applies to all patients and daily  assessments are 
to be performed only  for patients on IV study  drug.  Patients will receive IV treatment for a 
minimum of 72 hours (3 full day s, ie, 9 doses) before having the option to switch to an oral 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280 C00015
Edition Nu mber 2
Date 07 March 2017
42(88)therap y as specified in Section 7.7below.  The decision to switch to oral therapy  is entirel y at 
the Investigatorâ€™s discretion, if the patient has good or sufficient clinical response, and the 
patient is tolerating oral fluids or food.   
Patients can continue to take IV CAZ -AVI up to 
Day 15.  The following will be performed: 
ï‚·IV study  drug or oral switch therapy  administration
ï‚·Complete phy sical examination after completion of 72 hoursâ€™ treatment only.  This 
assessment may  be per formed on Day  3, depending on the timing of treatment 
administration.   Assessment should be performed no later than 8 hours after the 
72-hour time point.
ï‚·Recording of concomitant medications, including mother if patient is breast fed
ï‚·Vital signs 
ï‚·Recording of an y adjunctive therapeutic procedures performed
ï‚·Recording of an y AEs/SAEs
ï‚·Complete blood count with differential, chemistry  panel , and CrCl calculation to be 
conducted on Day 7 if the patient is still receiving IV study  drug at that time  
ï‚·If clinicall y indicated: urine sample for routine analysis, intra -abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional) , weight (if feasible) . 
Additionally , in instances of rapi[INVESTIGATOR_2478] y changing renal function, the Investigator should 
increase the frequency  of CrCl monitoring, depending on the patientâ€™s clinical status, 
extent of renal function change and the 
Investigatorâ€™s clinical evaluation .  Test results 
of an y samples taken as standard of care should be recorded in the CRF.
4.2.[ADDRESS_415504] infusion of study  drug or at the time of premature discontinuation 
of study  drug or earl y withdrawal from study (if on IV study drug).  The EOIV assessments 
should be conducted in place of the regular study  visit (eg, Day s 4 to â‰¤15) assessments that 
would have been performed the day  of that visit.  A patient may  be eligible to switch to oral 
therap y on or after Day 4 (
Section 7); EOIV assessments must occur before starting oral 
switch therap y.  The following will be performed: 
ï‚·Complete phy sical examination
ï‚·Recording of concomitant medications, including mother if p atient is breast fed
ï‚·Vital signs
ï‚·Recording of an y adjunctive therapeutic procedures performed
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
43(88)ï‚·If clinicall y indicated: urine sample for routine analysis, intra -abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional) , weight (if fe asible) . 
Additionally , in instances of rapi[INVESTIGATOR_2478] y changing renal function, the Investigator should 
increase the frequency  of CrCl monitoring, depending on the patientâ€™s clinical status, 
extent of renal function change and the Investigatorâ€™s clinical evaluati on.  Test results 
of an y samples taken as standard of care should be recorded in the CRF.
ï‚·Assessment of clinical outcome
ï‚·Recording of an y AEs/SAEs
ï‚·Complete blood count with differential
,chemistry  panel , and CrCl calculation . If 
EOIV occurs within 48 hours after these assessments are performed on Study  Day  7, 
these assessments should not be repeated.  
ï‚·Oral switch therap y administration
4.2.5 End of Treatment ( oral switch therapy)
The assessments at EOT should be performed in perso n within [ADDRESS_415505] dose of 
oral switch therap y or at the time of premature discontinuation of oral switch therap yor early  
withdrawal from study  (if on oral switch therapy ).  If a patient does not switch to oral therap y, 
the EOIV assessments 
should be conducted instead of the EOT assessments.  For patients 
receiving oral switch therapy  only, the following will be performed: 
ï‚·Complete phy sical examination
ï‚·Recording of concomitant medications, including mother if patient is breast fed
ï‚·Vital signs
ï‚·Recording of an y adjunctive therapeutic procedures performed
ï‚·If clinicall y indicated: CrCl calculation, urine sample for routine anal ysis, 
intra-
abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional) , weight (if feasible) . Additionally , in instances of rapi[INVESTIGATOR_336297], the Investigator should increase the frequency  of CrCl monitoring, depending 
on the patientâ€™s clinical status, extent of renal function change and the Investigatorâ€™s 
clinical evaluation .  Test res ults of an y samples taken as standard of care should be 
recorded in the CRF.
ï‚·Assessment of clinical outcome
ï‚·Recording of an y AEs/SAEs
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
44(88)4.3 Follow -up period
The procedures for this period are listed in the Study  Plan ( Table 1)
.  Details of study  
assessments are provided in Section 5.
4.3.[ADDRESS_415506] dose of 
any study  drug (IV or oral).  The following will be performed:
ï‚·Complete phy sical examination
ï‚·Recording of concomitant medications, including mother if patient is breas t fed
ï‚·Vital signs
ï‚·ECG (to be performed after the vital signs)
ï‚·Recording of an y adjunctive therapeutic procedures performed
ï‚·If clinicall y indicated: urine sample for routine analysis, intra -abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional) , weight (if feasible) . 
Additionally , in instances of rapi[INVESTIGATOR_2478] y changing renal function, the Investigator should 
increase the frequency  of CrCl monitoring, depending on the patientâ€™s clinical status, 
extent of renal function change and the Investigatorâ€™s clinical 
evaluation .  Test results 
of an y samples taken as standard of care should be recorded in the CRF.
ï‚·Assessment of clinical outcome
ï‚·Recording of an y AEs/SAEs
ï‚·Complete blood count with differential, chemistry  panel , and CrCl calculation tobe 
performed onl y if the patient had an abnormal (high or low) result at or after EOIV.  
ï‚·Direct Coombs test
ï‚·Serum pregnancy  test
4.3.[ADDRESS_415507] dose of any stud y drug ( IV 
or oral).  The LFU visit may  be conducted via telephone for any  patient who has not 
experienced clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop 
AEs or SAEs since TOC.  If s ymptoms of relapse or new AEs or SAEs are noted, or at the 
discretion of the Blinded Observer or Investigator, the patient should be immediately  
scheduled for an in -person visit.  The following will be assessed at LFU: 
ï‚·Complete phy sical examination (not applicable if visit conducted by  [CONTACT_756])
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibac tam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
45(88)ï‚·Recording of concomitant medications, including mother if patient is breast fed
ï‚·Vital signs (not applicable if visit conducted b y telephone)
ï‚·Recording of an y adjunctive therape utic procedures performed
ï‚·If clinicall y indicated: CrCl calculation, urine sample for routine anal ysis, 
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional) , weight (if feasible) . Additionally , in instances of rapi[INVESTIGATOR_336297], the Investigator should increase the frequency  of CrCl monitoring, depending 
on the patientâ€™s clinical status, extent of renal function change and the Investigatorâ€™s 
clinical evaluation .  Test results of any  samples taken as standa rd of care should be 
recorded in the CRF.
ï‚·Assessment of clinical relapse
ï‚·Recording of an y AEs/SAEs
5. STUDY ASSESSMENTS
5.1 Efficacy assessments 
Clinical outcome, relapse, and emergent infections will be assessed b y the Blinded Observer 
at the time points specif
ied in Table 
1.  The Blinded Observer will assess clinical outcome, 
(including at LFU, assessment of patients for clinical relapse) and collection andreporting of 
AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days 
after an y dose of stud y drug ( IV or oral) or LFU. 
5.2 Microbiological assessments
Culture and organism identification should be performed at the local or regional laboratory , as 
applicable.  Susceptibility testing should be done at the local or regional laboratory  to support 
patient care.  All isolates should be sent to the central laboratory  for organism identification 
and susceptibility  testing.
Refer to the study -specific clinical and microbiology  laboratory  manual for specific 
procedures pertaining to the collection, processing, storage, and shipment of intra -abdominal 
fluid and blood culture samples or isolates.
5.2.1 Intra-
abdominal fluid for microbiologica l culture
Intra -abdominal fluid samples (such as tissue or aspi[INVESTIGATOR_336299]) should be obtained for culture at Baseline (preferably  before any  
antibiotics are administered) for all patients and at any  time until LFU, if clinically  indicated 
and performed as part of the patientâ€™s regular medical care.  Baseline intra-abdominal fluid 
samples for culture must be obtained from the site of abdominal infection during surgical 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
46(88)intervention.  Intra -abdominal flu id samples should be collected onl y when collection of a 
sample is medically  feasible.   If a sample is collected, isolation of bacteria and susceptibility 
testing on identified bacteria should be done b y the local or regional laboratory per the 
laboratory â€™
s standard processes. In cases where the number of potential pathogens seen in the 
initial culture is numerous, the local or regional laboratory  should follow standard processes in 
identify ing pathogens causing the intra- abdominal infection. All pathogen sprepared and 
evaluated should be sent to the central laboratory for reconfirmation.   
5.2.2 Blood samples for microbiological culture
If clinicall y indicated, blood samples (1 mL) may be obtained for culture at Baseline 
(preferabl y before an y antibiotics are a dministered) and at an y time until LFU.  
This protocol complies with European Unionâ€™s recommendations for blood loss associated 
with paediatric research ( European Commission 2008 ) and the World Health Organisation 
guidelines â€œBlood Sample Volumes in Child Health Research: Review of Safe Limitsâ€ 
(Howie 2011 ).  To minimise risk from blood loss associated with this study , standard of care 
laboratory  results will be used whenever possible.  I n addition, paediatric blood collection 
tubes will be used and capi[INVESTIGATOR_336300].  PK samples will be collected from patients unless deemed unsafe due to the risk 
from additional blood loss (per the Investigatorâ€™s judgment).
5.3 Safety assessments
5.3.1 Laboratory safety assessments
Blood and urine samples for determination of clinical chemistry , haematology , and urinal ysis 
will be taken at the times indicated in Table 1.
The following laboratory variables will be measured:
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
47(88)Table 2 Laboratory safety variables
Comprehensive Metabolic 
Panel Haematology Urinalysis
Magnesium HaematocritaUrinalysis (routine and 
microscopy) will be performed 
according to the study centreâ€™s 
standard procedures
Bicarbonat e Haemoglobin
Sodium Erythrocyte count
Potassium Mean cell volume
Phosphorus Leukocyte count (WBC)
Chloride Neutrophils
Calcium Lymphocytes
Alkaline phosphatase Monocytes
Gamma glutamyltransferase Eosinophils
ALT Basophils
AST Platelets
Creatine kinase Immunohaematology
Lactate dehydrogenase Coombs test (direct)
Total bilirubin Pregnancy testing
Indirect bilirubin Serum Î² -hCG (females only)
Glucose, non- fasting Inflammation index
Creatinine CRP (optional)
Blood urea nitrogen Erythrocyte sedimentation rateb
Note: any other laboratory parameter that is deemed to be important as per local practices can be assessed if 
considered necessary, but will not be part of the required laboratory parameters as per protocol.  
Assessment of any additional laboratory parameters should not impact the blood volume to be drawn. 
aIf a patientâ€™s haemoglobin or haematocrit decreases significantly (in the Investigatorâ€™s judgment) after 
administration of the CAZ -AVI infusion, a w orkup for haemolytic anaemia should be performed per 
standard of care. 
bTo be collected if clinically indicated or if required per standard of care.
Additional safet y samples may be collected if clinically indicated at the discretion of the 
Investigator.  The date, time of collection and results (values, units and reference ranges) will 
be recorded on the appropriate CRF.
The clinical chemistry , haematology  and urinal ysis will be performed at a local laboratory  at 
or near to the Investigator site.  Sample tubes and sample sizes may  vary  depending on 
laboratory  method used and routine practice at the site.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidim e-avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
48(88)The Direct Coombs test is required at Baseline and TOC only . 
The Investigator should make an assessment of the available results with regard to clinicall y 
relevant abnormalities.  The laboratory  results should be signed and dated and retained at 
centre as source data for laboratory  variables.  For information on how AEs based on 
laboratory  tests should be recorded and reported, see Section 
6.3.
NB. If a patient shows an AST orALT â‰¥3Ã—ULN ortotal bilirubin â‰¥2Ã—ULN please refer to 
Appendix D for further instructions.
Creatinine clearance will be measured at Baseline and at each time that serum cre atinine is 
being assessed as part of the clinical chemistry  panel using the childâ€™s measured height 
(length) and serum creatinine within the updated â€œbedsideâ€ Schwartz formula ( Schwartz et al 
2009
). It is recommended that serum creatinine, and therefore CrCl obtained using the 
Schwartz bedside formula, are assessed at additional time points if the I nvestigator deems that 
the test is required for the sa fety of the patient, based on previous results and the patientâ€™s 
clinical condition, and if the additional test(s) does not exceed the maximum volume of blood 
allowed per protocol.  The Investigator should also consider the balance of the risk and benefit 
of taking additional samples when making the decision.  I f a biochemistry  panel is requested 
and serum creatinine can be added and evaluated without increasing the volume of blood 
allowed per protocol, the site should record the result in the CRF.   Note: measurement of 
height is not required at each point that CrCl is estimated : 
CrCl (mL/min/1.73m2)=0.413Ã—height (length) (cm)/serum creatinine (mg/dL)
If there is a significant reduction (according to the Investigator) in a patientâ€™s estimated CrCl 
during t he treatment period, the Investigator should contact [CONTACT_336343]
.
5.3.2 Physical examination 
A complete ph ysical examination will be performed and will include an assessment of the 
following: general appearance, skin, head and neck  (incl uding ears, ey es, nose and throat), 
lymph nodes, thy roid, respi[INVESTIGATOR_696] , cardiovascular, abdomen, musculoskeletal (including spi[INVESTIGATOR_336301]) and neurological s ystems . Height and weight will be measured at Baseline 
only.  Weight may  be measured at subsequent time points if clinically  indicated and feasible .  
Body mass index (BMI) (kg/m2) will be calculated as the ratio of weight in kg/(height in 
cm/100)2.  BMI will only be calculated at Baseline (Day  -1/Day 1).  BMI will not be 
calculated for children <2years of age (Cohort s 4a and 4b ) as BMI is not considered a 
screening tool for healthy weight in children <2 years of age.  Tanner staging of development 
(refer to 
Appendix E for further details on Tanner staging) will be assessed at Baseline only  
(Day  -1/Day 1) for females who have not reached menarche but may  reasonably  have the 
potential to become pregnant.  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
49(88)5.3.3 Electrocardiogram
A single 12 -lead (or as appropriate per Investigator decision) ECG recording will be 
performed at the times indicated in Table [ADDRESS_415508] 10 minutes.  The 
results for the ECG will be paper reports provided locally  for safet y revi ew by  [CONTACT_3786].  
Each ECG will be interpreted as appropriate for the patientâ€™s age.
5.3.[ADDRESS_415509] temperature of the day  should be recorded in the CRF.
[IP_ADDRESS] Pulse and blood pressure
Supi[INVESTIGATOR_336302].  The patients will be required to rest in 
the supi[INVESTIGATOR_21683] 10 minutes prior to heart rate and blood p ressure 
measurements.  For timings of vital signs assessments refer to Table 1.
[IP_ADDRESS] Body temperature
Body temperature will be measured in degrees Celsius using an automated thermometer at the 
times indicated in Table 1and the actual time of body  temperature collection will be recorded.  
For each indivi dual patient, the method of temperature measurement (oral, rectal, temporal, 
axillary , or t ympanic, as appropriate) ideall y should be consistent for the duration of the study.  
[IP_ADDRESS] Respi[INVESTIGATOR_336303] e times indicated in Table 1.
5.3.5 Cephalosporin class effects
In addition to AE and SAE monitoring as described in 
Section 6, cephalosporin class effects 
and additional AEs will also be closely  monitored (including, but not limited to seizures, 
C.difficile -associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic anaemia 
and changes in renal function).
5.[ADDRESS_415510] cannot be obtained prior to dosing 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
50(88)of investigational product, a urine pregnancy  test may  be done at Baseline though a serum 
Î²-hCG test result must still be obtained.
If performed, adjunctive therapeutic procedures will be recorded throughout the treatment 
period until TOC. 
Radiological examinations are not required for the study
, but the results should be recorded if 
done as part of the diagnosis.  Radiological examinations include WBC scans, plain 
abdom inal radiographs, CT scans, ultrasound and/or MRI  scans with or without contrast.  
5.5 Pharmacok inetics
5.5.1 Collection of samples
Blood samples (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3 , 
4a,and 4 b) for determination of ceftazidime and avibactam in plasma will be taken at the 
times presented in Table 1in a manner such that the Blinded Observer remains blinded (ie, the 
Investiga tor should collect the samples).  The date and time of sample collection will be 
recorded, as well as the date and time of the dose of IV study  therap y immediatel y preceding 
the sample collection.
Samples will be collected, labelled, stored and shipped as detailed in the Laboratory  Manual. 
5.5.2 Determination of drug concentration
Samples for determination of ceftazidime and avibactam concentration in plasma will be 
analysed by [CONTACT_76434], using an appropriate bioanalytical method.  
Full de tails of the analy tical method used will be described in a separate bioanal ytical report.
5.5.3 Storage and destruction of pharmacokinetic samples
Pharmacokinetic samples will be disposed of after the Bioanal ytical Report finalisation 
or 6months after issuance of the draft Bioanal ytical Report (whichever is earlier), unless 
requested for future analyses. 
Pharmacokinetic samples may  be disposed of or destroy ed or anony mised by  [CONTACT_76435]. 
Additional analy ses may  be conducted on the anony mised, pooled PK samples to further 
evaluate and validate the anal ytical method. Any results from such anal yses may  be reported 
separately  from the Clinical Study  Report (CSR).
Incurred sample reproducibility  anal ysis, if an y, will be performed alongside the bioanal ysis 
of the test samples.  
The results from the evaluation will not be reported in the CSR but 
separately  in a Bioanal ytical Report.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
51(88)5.[ADDRESS_415511] 
by [CONTACT_336344] (ie, complete blood count with 
differential, chemistry  panel, Direct Coombs test, pregnancy testing, and PK anal yses) is to be 
no mor e than 2.4 cc/kg. Any deviation from this should be clinically  justified.
Table 3 Volume of blood per patient â€“ Cohorts 1 and 2
Blood 
Volume 
(mL)Day Baseline Day 3 EOIV TOCTotals 
(minimum 
blood 
volume)
Chemistry [ADDRESS_415512]
Coombs1.5 1.5 3
Serum 
pregnancy2 2 4
PK 3 3
Totals 6.25 3 2.75 6.25 18.25
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
52(88)Table 4 Volume of blood per patient â€“ Cohorts 3, 4a, and 4 b
Blood 
Volume 
(mL)Day Baseline Day 3 EOIV TOCTotals 
(minimum 
blood 
volume)
Chemistry [ADDRESS_415513].  An undesirable medical condition 
can be s ymptoms (eg, nausea, chest pain), signs (eg, tachy cardia, enlarged liver) or the 
abnormal results of an investigation (eg, laboratory  findings, ECG).  In clinical studies, an AE 
can include an undesirable medical condition occurring at an y time, including run -in or 
washout periods, even if no study  treatment has been administered.
The term AE is used to include both serious and non -serious AEs.
6.2 Definition of serious adverse event
An SAE is an AE occurring during an y study phase (ie, run- in, treatment, washout, 
follow -up), that fulfils 1 or more of the following criteria:
ï‚·Results in death
ï‚·Is immediatel y life -threatening
ï‚·Requires in-patient hospi[INVESTIGATOR_15574] 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
53(88)ï‚·Results in persistent or significant disability /incapacity  or substantial disruption of the 
ability  to conduct normal life functions
ï‚·Is a congenital abnormality  or birth defect
ï‚·Is an important medical event that may  jeopardise the patient or may  require medical 
intervention to prevent one of the outcomes listed above
For further guidance on the definition of a SAE, see Appendix B.
6.3 Recording of adverse events
6.3.1
Time period for collection of adverse events
Non-serious AEs and SAEs will be collected for each patient from the time of signature [CONTACT_86220]/assent until the L FU visit ( 27 to 50 day s after start of study  treatment) .
6.3.2 Follow -up of unresolved adverse events
Any AEs that are unresolved at the patientâ€™s last visit in the study  are followed up 
by [CONTACT_336345] y indicated.  [COMPANY_008] and its 
representatives retain the right to request additional information for an y patient
with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary .
6.3.3 Variables 
The following variables will be collected for each AE:
ï‚·AE (verbatim)
ï‚·Date and time when the AE started and stopped
ï‚·Maximum intensity
ï‚·Whether the AE is seriou s or not
ï‚·Blinded Observer causality  rating against the IV study  therapy  (yes or no) and against 
metronidazole (y es or no)
ï‚·Action taken with regard to I V study  therapy
ï‚·Outcome of AE
In addition, the following variables will be collected for SAEs:
ï‚·Onset Date (date AE met criteria for serious AE)
ï‚·Detection date (date Investigator became aware of serious AE)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Pr otocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
54(88)ï‚·AE is serious due to:
(a) Death, if fatal outcome, the following will be collected:
ï€­Date of death
ï€­Autopsy  performed
ï€­Primary /secondary  cause of death
(b) Life threatening
(c) Inpatient hospi[INVESTIGATOR_15574] (note: patients 
will be hospi[INVESTIGATOR_336304] .  The initial hospi[INVESTIGATOR_336305], the hospi[INVESTIGATOR_336306])
ï€­Date of hospi[INVESTIGATOR_11956]
ï€­Date of discharge
(d) Congenital abnormality  or birth defect
(e) Important medical event
(f) Suspected transmission via a medicinal product of an infectious agent
ï‚·Blinded Observer c ausality  assessment in relation to study  procedures (y es/no)
ï‚·Blinded Observer c ausality  assessment in relation to other medication (y es/no)
ï‚·Description of AE
It is important to distinguish between serious and severe AEs.  Severit y is a measure of
intensity  whereas seriousness is defined by  [CONTACT_29967].  An AE of severe intensit y need 
not necessaril y be considered serious.  For example, nausea that persists for several hours may  
be considered severe nausea, but not a SAE.  On the other hand, a stroke that results in only  a 
limited degree of disability  may  be considered a mild stroke but would be a SAE.  The 
Blinded Observer should provide an assessment of the severit y of each AE/SAE.
6.3.4 Causality collection
The Blinded Observer will assess causal relationship between IP and each AE, and answer 
â€˜yesâ€™ or â€˜noâ€™ to the question â€˜Do y ou consider that there is a reasonable possibility  that the 
event may  have been caused by  [CONTACT_7198]?â€™
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
55(88)For SAEs , the Blinded Observer will also asses scausal relationship for other medication and 
study  procedures and additional study  drug.  Note that for SAEs that could be associated with 
any study  procedure the causal relationship is implied as â€˜y esâ€™.
A guide to the interpretation of the causalit y que stion is found in Appendix B
.
6.3.5 Adverse events based on signs and symptoms
All AEs spontaneously  reported by  [CONTACT_336346]: â€˜Have you/the child had any health problems since
the previous visit/you were last asked?â€™ , or revealed by  [CONTACT_336347].  When collecting AEs, the recording of diagnoses is preferred (when 
possible) to recording a list of signs and s ymptoms.  However, if a diagnos is is known and 
there are other signs or symptoms that are not generall y part of the diagnosis, the diagnosis 
and each sign or s ymptom will be recorded separately .
6.3.6 Adverse events based on examinations and tests
The results from protocol -mandated laboratory tests and vital sign measurements will be 
summarised in the CSR.  Deterioration as compared to Day  1 (Baseline) in protocol -mandated 
laboratory  values, vital signs, ECGs, and other safety  assessments should therefore onl y be 
reported as AEs if they  fulfil any of the SAE criteria or are the reason for discontinuation of 
treatment with the IV study  therapy .
If deterioration in a laboratory value or vital sign is associated with clinical signs and 
symptoms, the sign or s ymptom will be reported as an AE and th e associated laboratory  result 
or vital sign will be considered as additional information.  Wherever possible, the reporting 
Investigator uses the clinical, rather than the laboratory term (eg, anaemia versus low 
haemoglobin value).  In the absence of clin ical signs or sy mptoms, clinically  relevant 
deteriorations in non -mandated parameters should be reported as AE(s).
Deterioration of a laboratory  value, which is unequivocally  due to disease progression, should 
not be reported as an AE or SAE (see Section [IP_ADDRESS]).
Any new or aggravated clinically  relevant abnormal medical finding at a phy sical examination 
as compared with the screening assessment will be reported as an AE.
6.3.7 Actions required in cases of increases in liver chemistry values
The Investigator is responsible for, without delay , determining whether the patient meets 
potential Hy â€™s law criteria; AST or ALT â‰¥3Ã—ULN andtotal bilirubin â‰¥2Ã—ULN irrespective of 
the value of the patientâ€™s alkaline phosphatase, at any  point during the study following the 
start of study medication.
A Hy â€™s Law case is defined as study  patient with an increase in serum AST or ALT 
â‰¥3Ã—ULN 
together with total bilirubin â‰¥2Ã—ULN, where no other reason can be found to explain the 
combination of increases, eg, elevated serum ALP indicating cholestasis, viral hepatitis, or 
another drug.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
56(88)For potential Hy â€™s Law and Hy â€™s Law the elevation in transaminases mu st precede or be 
coincident with (ie, on the same day ) the elevation in total bilirubin, but there is no specified 
timeframe within which the elevations in transaminases and total bilirubin must occur.  
Details regarding the actions required in the cases of increases in ALT, AST, and total 
bilirubin can be found in 
Appendix D.
If a patient reaches an ALT or AST=5Ã—ULN, the patient may  continue with the I P as planned 
unless discontinuation criteria as described in Section 3.10 are met.  The patient should be 
seen within 48 hours to instigate enhanced follow -up and monitoring.  Enhanced follow -up 
should include collection of clinical and historical information to determine the cause of ALT 
and/or AST elevations.  Additional testing for liver laboratory  test results must be done every  
48 hours until the peak value has been reached as documented by  a decline in the values
and/or until the patient is feeling better.  The frequency  of retesting can decrease to once per 
week or less if abnormalities stabilise or study  drug has been discontinued and the patient is 
asymptomatic.  The patient should be followed until resolution (including laboratory  testing).
6.3.[ADDRESS_415514] adverse event collection
[IP_ADDRESS] Lack of Effect
Where there is deterioration in the condition for which the IV study  therap y is being used, 
there may  be uncertainty  as to whether this is lack of efficacy , disease progression, and 
whether it constitutes an AE.  In such cases, unless the [COMPANY_008] or reporting ph ysician 
considers that the IV study therapy contributed to the deterioration or local regulations state 
the contrary , the deterioration should be considered to be lack of efficacy  and not an AE.
Insufficient therapeutic effect will be captured as an efficacy  outcome.  Instances of, or 
discontinuation due to insufficient therapeutic effect (ie, lack of efficacy ) should not be 
collected as AEs.  A clinic al failure should not be recorded as an AE.
[IP_ADDRESS] Disease progression
Disease progression can be considered as a worsening of a patientâ€™s condition attributable to 
the disease for which CAZ- AVI is being studied.  It may  be an increase in the severit y of the 
disease under stud y and/or increases in the s ymptoms of the disease.  Expected progression of 
the disease under study  and/or expected progression of signs and s ymptoms of the disease 
under study , unless more severe in intensit y or more frequent than expected f or the patientâ€™s 
condition, should not be reported as an AE.  An y event or extended hospi[INVESTIGATOR_336307] y due to disease progression must not be reported as an SAE unless it is believed 
that I V study  therapy  actively  contributed to the prog ression of the disease (ie, not by  [CONTACT_336348]).  Events that are unequivocall y due to disease progression 
should not be reported as an AE during the stud y.
6.[ADDRESS_415515] to be reported, whethe r or not considered causall y related to the I P, or to the 
study  procedure(s). All SAEs will be recorded in the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
57(88)If any SAE occurs in the course of the stud y, then Investigators will enter SAE information 
into the Electronic Data Capture s ystem within [ADDRESS_415516] all SAE information to the [COMPANY_008] Patient Safet y data 
entry  site within 1 calendar day of initial receipt for fatal and life threatening events (if 
received for instance during a weekend or a public holiday , the information is forwarded as 
early as possible on the first business day following the weekend or holiday) and within 
3calendar days of initial receipt for all other SAEs.
For fatal or life -threatening AEs where important or relevant information is missing, active 
follow -up is undertaken immediately .  Investigators or other site personnel inform PRA 
representatives of an y follow -up information on a previously  reported SAE within [ADDRESS_415517] information for SAE reporting: 
FAX: [PHONE_6981]
E-mail: MHGsafet [EMAIL_6528]
Telephone: [PHONE_6982]
PRA, on behalf of [COMPANY_008], is responsible for reporting cert ain SAEs as expedited safet y 
reports to applicable regulatory  authorities, Ethics Committees, and participating 
Investigators, in accordance with International Conference on Harmonisation (I CH) 
Guidelines and/or local regulatory  requirements.  PRA may  be required to report certain SAEs 
to regulatory  authorities within 7 calendar day s of being notified about the event; therefore, it 
is important that I nvestigators submit additional information requested by  [CONTACT_336349].
The reference document for definition of expectedness/listedness is the I nvestigatorâ€™s 
Brochure for the [COMPANY_008] drug CAZ -AVI and the EU Summary  of Product Characteristics 
for the active comparator product (including an y [COMPANY_008] comparator). 
6.5 Overdo se
Overdose is defined as a dose administered to a patient in excess of that specified in this 
protocol. Overdose does not automatically  make an AE serious but if the consequences of the 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
58(88)overdose are serious for example death or hospi[INVESTIGATOR_11956], the event is serious and should be 
reported as such.
Recording an overdose will be done according to the following:
ï‚·An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF and on the Overdose CRF module.
ï‚·An overdose without associated s ymptoms is only reported on the Overdose CRF 
module.
ï‚·If an overdose on an [COMPANY_008] IV study  therapy  occurs in the course of the study , 
then I nvestigators or other study  centre personnel will inform appropriate [COMPANY_008] 
representatives within 1 day, ie, immediately  but no later than the end of the next 
business day  from when he or she becomes aware of it.
ï‚·The designated [COMPANY_008] representative works with the I nvestigator to ensure that 
all relevant information is provide d to the [COMPANY_008] patient safet y data entry site.
ï‚·For overdoses associated with an SAE, standard reporting time lines appl y, see 
Section 6.4. For other overdoses, reporting should be done within [ADDRESS_415518] interfered with the effectiveness of a contraceptive medication.  Congenital 
abnormalities/birth defects and spontaneou s miscarriages should be reported and handled as 
SAEs.  Elective abortions without complications should not be handled as AEs.   The outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy , normal 
birth or congenital abn ormality ) should be followed up and documented even if the patient 
was discontinued from the study .
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 
informs the PRA Drug Safet y Department immediately but no later than 24 hours of when 
he or she becomes aware of it .
PRA works with the I nvestigator to ensure that all relevant information is provided to the PRA 
Drug Safet y Department within 1 or 3 calendar days for SAEs (see Section 6.4) and within 
30 days for all other pregnancies .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
59(88)The same timelines apply  when outcome information is available.
All outcomes of pregnancy  should be reported to the PRA Drug S afety Department .  An y 
patient who becomes pregnant during the course of the study  will be followed so that 
pregnancy  outcome can be determined and reported to [COMPANY_008] and the regulatory  
authorities.
A pregnancy  report form ( electronic cop y of the PREG REP form ) will be used to report the 
pregnancy  to the PRA Drug Safety  Department .  
The outcome of the pregnancy  will be 
reported on the pregnancy  report form (paper copy  of the PREGOUT form) and provided by  
[CONTACT_336350] , but the outcome of the pregnancy  will not be 
documented in the clinical database.
6.6.2 Paternal exposure 
There is no restriction on fathering children or donating sperm during the study .  Pregnancy  of 
the patientâ€™s partner is not considered to be an AE.  However, the outcome of all pregnancies 
(spontaneous miscarriage, elective termination, ectopic pregnancy , normal birth, or congenital 
abnormality ) should if possible be followed up and documented.  The outcome of an y 
conception occurring from the date of the firs t IP administration until [ADDRESS_415519] included 
tremors, my
oclonus, seizures, encephalopathy , and coma.  Patients who receive an acute 
overdosage should be carefully  observed and given supportive treatment.  In the presence of 
renal insufficiency , haemodialy sis or peritoneal dialy sis may  aid in the removal of ceftazidime 
from the bod y.  Continued dosage should be determined by [CONTACT_13437], 
severit y of infection, and susceptibility  of the causative organisms. 
Cephalosporins may  be associated with a fall in prothrombin activity .  Those at risk include 
patients with renal and hepatic impairment, or poor nutritional state, as well as patients 
receiving a protracted course of antimicrobial therapy .  Prothrombin time should be monitored 
in patients at risk and exogenous vitamin K administered as indicated.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised C linical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
60(88)6.8 Study governance and oversight
The safet y of all [COMPANY_008] clinical studies is closely  mon itored on an on -going basis b y 
[COMPANY_008] representatives in consultation with Patient Safety .  Issues identified will be 
addressed; for instance this could involve amendments to the study  protocol and letters to 
Investigators.
6.8.[ADDRESS_415520] (DSMB ) is deemed 
necessary  since the trial has a long period of enrolment, is multi -centre and multi
-national, and 
represents one of the first safet y and efficacy trials of CAZ -AVI in children.  
The DSMB is charged with reviewing and evaluating the study  safet y (AEs, SAEs, and 
potentially  clinicall y significant laboratory results) at per iodic intervals.  The DSMB members 
will be familiarised with AEs and SAEs likely  to occur in this patient population, based on 
experience in adults and adolescents, as well as with this class of drugs (cephalosporins).  The 
DSMB will conduct pre -planned and possibly  ad hoc reviews of accumulating data.
Based on the findings of these reviews, the DSMB may make recommendations to 
[COMPANY_008] regarding the study , including, but not limited to: continue the study without 
modification, modify  the protocol or inf ormed consent/assent document(s), or temporaril y 
stop enrolment in all or some of the study  centres.  [COMPANY_008] will be responsible for 
discussing and, if considered appropriate, implementing the DSMB recommendations.  
Further details can be found in the DSMB charter. 
7. INVESTIGATIONAL PROD UCT AND OTHER TREATM ENTS
7.[ADDRESS_415521](s)
Investigational product Dosage form and strength
CAZ -AVI Ceftazidime avibactam powder for concentrate for solution for 
infusion 2000 mg/[ADDRESS_415522] package insert, label, and local dosing guidelines for 
further information reg arding dosage, administration, storage, maximum doses, 
contraindications, warnings, precautions, and AEs reported.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
61(88)7.2 Dose and treatment regimens
The study  is single blind, ie, a Blinded Observer will not know the patientâ€™s treatment 
assignment and will condu ct clinical assessments (including efficacy  and safety ).  There is no 
use of placebo to act as a treatment blind.
The dose sof CAZ -AVI arebased on age and weight with adjustment according to renal 
function as detailed in Table 5.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
62(88)Table 5 CAZ -AVI dose s by [CONTACT_654], weight, and creatinine clearance
Cohort Age range Body 
weightCAZ -AVI dose
CrCl â‰¥50 mL/minCAZ -AVI dose
CrCl â‰¥30 to <50 mL/min
CAZ -AVI must be administered as a 50 to 100 mL infusion (dependent on dose) over 
2hours every 8 hours (Â±30 minutes)
1112 years to 
<18yearsâ‰¥40kg 2000 mg ceftazidime/500 mg avibactam 1000 mg ceftazidime/250 mg avibactam
1112 years to 
<18years<40kg 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
216 years to 
<12yearsâ‰¥40kg 2000 mg ceftazidime/500 mg avibactam 1000 mg ceftazidime/250 mg avibactam
216 years to 
<12years<40kg 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
312 years to 
<6yearsAll 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4a21year to <2 years All 50 mg/kg ceftazidime /12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b26months to 
<1yearAll 50 mg/kg ceftazidime/12.5 mg/kg avibactam 25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b23months to 
<6monthsAll 40 mg/kg ceftazidime/10 mg/kg avibactam 20 mg/kg ceftazidime/5 mg/kg avibactam
1Patients considered for entry into the study will be within the normal range of BMI for their age, (2 to <18).  A healthy wei ght BMI for this age group 
falls between the 5th percentile and â‰¤95th percentile according to height, weight, and age.
2BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in child ren under 2 years of age.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global R evised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
63(88)Full details of infusion prepa ration are given in the Pharmacy  Manual.
Patients whose CrCl changes during treatment should receive the appropriate dose reduction 
or increase according to Table 5.
The Investigator should follow the package insert for meropenem for dose modifications 
associated with renal impairment.
Patients whose CrCL  drops below 30 mL /min should be withdrawn from study  therapy .  
Patients withdrawing from study  therap y can be administered alternative therapi[INVESTIGATOR_336281]â€™s choice, which should be recorded in the CRF .  If possible, patients should still 
be followed for safety (see 
Section 3.9.1).  Because the CrCl determination is only  an estimate 
of renal function, in instances where the CrCl is approaching thresholds that would require 
intervention such as a dose cha nge or discontinuation of therapy  (ie CrCL approaching 50 or 
30 mL /min) , the Investigator should use his or her discretion in determining (ie confirming the 
value b y repeat testing, if feasible) whether an immediate dose change, a short period of 
continued observation, or discontinuation of therapy  is warranted. If in the opi[INVESTIGATOR_336308] a clinically  significant reduction in a patientâ€™s estimated CrCl during the 
treatment period, then the Investigator should contact [CONTACT_336324] (immediate dose change, a short period of continued observation, or 
discontinuation of therapy ). Additionally , in instances of rapi[INVESTIGATOR_336282], the 
Investigator should increase the frequency  of CrCl monitoring, depending on the patientâ€™s 
clinical status, extent of renal function change and I nvestigatorâ€™s clinical evaluation.
The suggested dosing regimen of m etronidazole is10mg/kg IV over 20 to 30 minutes every  
8hours 
(Â±30 minutes), but it can also beprescribed/adjusted by  [CONTACT_336325]. The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ -AVI infusion.  
The dose/regimen of meropenem will be 20 mg/kg every  8hours (Â±1hour) infused over 
approximately  15 to 30 minutes or up to 1 hour ( or infusion duration as per local guidelines
).  
For patients weighing over 50 kg, the maximum dose of meropenem should not exceed 1 g 
every  8 hours.  The time interval between the beginning of r econstitution and the end of the 
infusion should not exceed 1 hour due to the stability  of meropenem when reconstituted with 
sodium chloride. 
7.3 Labelling
Labels will be prepared in accordance with Good Manufacturing Practice and local regulatory  
guidelines.  
Label text will be translated into the local language.
Personnel at the study  centre will prepare and label the individual I V infusions as assigned by  
[CONTACT_4150], and according to the handling instructions.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
64(88)7.[ADDRESS_415523] under appropriate storage conditions.  The 
storage conditions will be stated on the stud y drug labelling and in the handling instructions.
7.5 Compliance
The site will monitor patient compliance, which will be documented in the patientâ€™s source 
documents, and relevant data will be reported in the CRF.  To ensure that the patient is 
compliant with administration of study  drug, oral switch therapy , and stud y procedures, the 
date and dose of the medication should be recorded in the appropriate section s of the CRF.  
7.6 Accountability
The study  drug provided for this study  will be used only  as directed in the study  protocol.
The study  personnel will account for all study  drugs dispensed to and returned from the 
patient.
Study  site personnel, if applicable, or the PRA monitor will account for all study  drugs 
received at the site, unused study  drugs and for appropriate destruction.  Certificates of 
delivery , destruction, and return should be signed.  For general drug destruction (eg, left over 
drug at site), accepted practices for destruction within specific sites, countries, or regions 
should be used, through PRAâ€™s standard operating procedures (SOPs).  Therefore, where at all 
possible the I P should be destroy ed locall y at site and a third part y supplier for return and 
destruction should only
 be used where specific country  regulations or local procedures state 
this is not possible. Documentation should be provided by [CONTACT_336351]â€™s Research 
and Development Procurement Manager identify ing that this is the case. For I P associated 
with a recall, [COMPANY_008] will determine what is to be destro yed, but PRA will manage the 
execution of destruction using standards acceptable to [COMPANY_008] or its representative.
7.7 Oral switch therapy
The choice of oral switch ther apy, among the options listed below, should be in line with the 
approved and marketed drugs in the respective country , and should observe the local speci fic 
regulations and local therapeutic guidelines (if existent), regarding posology.  The decision to 
switch to oral therap y is entirely at the Investigatorâ€™s discretion, if the patient has good or 
sufficient clinical response, and the patient is tolerating oral fluids or food.
For the optional oral switch therap y, the following should be given: 
ï‚·Oral amoxi cillin/clavulanic acid ( only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or
ï‚·Oral ciprofloxacin ( only in countries where its use for children is permitted ; according 
to local guidelines, administered at a dose and formulation per standard of care) plus 
metronidazole (administered at a dose and formulation per standard of care), or
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
65(88)ï‚·Pathogen -based therapy (in discussion with the Medical Monitor) .  The choice of oral 
antibacterial agent for pathogen -based therapy  will be driven by  [CONTACT_109972] a 
susceptibility  test, which will be provided tothe Investigator b y either the local or 
central laboratory .  Initiation of pathogen
-based therap y is at the Investigato râ€™s 
discretion.  Before administering pathogen -based therap y, the Investigator will discuss 
the results of the susceptibility  test and the selected antibacterial drug (which should be 
approved for use in children) with the Medical Monitor . 
The optional or al switch therapi[INVESTIGATOR_336309] y centres and PRA.
Consult the Summary  of Product Characteristics or product package insert, label, and local 
dosing guidelines for further information re
garding dosage, administration, storage, maximum 
doses, contraindications, warnings, precautions, and AEs reported.
7.8 Concomitant and other treatments 
All prescription and over -the-counter medications being taken by  [CONTACT_336352] 2 weeks 
prior to stud y entr y (considered prior treatment) and from randomisation through the LFU 
visit (considered concomitant treatment) must be documented on the appropriate pages of the 
CRF.  Sy stemic antibiotics should be documented for the entire duration of the study  (from 
2weeks prior to stud y entry through the LFU visit).  For patients who are being breast fed, all 
medications taken b y the lactating mother in the previous [ADDRESS_415524] dose of 
study  therapy  until LFU will also be recorded.
If Enterococcus species or methicillin -resistant staphylococcus aureus (MRSA) is one of the 
pathogens suspected or isolated and, in the opi[INVESTIGATOR_689], specific therap y is 
indicated, then open -label vancomy cin, linezolid, or daptomy cin may  be added to either of the 
study  regimens according to the usual practice of the I nvestigator.  If vancomy cin, linezolid, 
or daptomy cin are started empi[INVESTIGATOR_336310], and if final 
culture results did not isolate MRSA or Enterococcus species, then the Investigator should 
discontinue the additional Gram -positive coverage that was empi[INVESTIGATOR_60519] y added.
The use of other s ystemic antimicrobials not specified by  [CONTACT_336353] .  Antibiotic peritoneal lavage andperitoneal lavage with saline or other 
non-antibacterial contain ing solution are allowed.  Topi[INVESTIGATOR_336311].  
Other medication, which is considered necessary  for the patientâ€™s safet y and well -being, may  
be given at the discretion of the Investigator and recorded in the appropriate sections of the 
CRF.  If analgesic medications are needed for pain, the use of analgesic medication without 
antipy retic properties is preferred.  Should a patient require immunosuppressive agents or 
chemotherap y after being randomised to IV study  therap y, the Investigator should contact [CONTACT_336354] (as an [COMPANY_008] delegate) before initiating therapy.  Continued 
patient study  participation will be determined based upon assessment of the sa fety risk to the 
patient if he or she were to continue in the study .  Patients who have completed IV study  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
66(88)therap y and are in the follow -up (FU) period should remain in the study  as they  are not 
activel y on IV stud y therapy but being followed for outcomes.
Simultaneous administration of meropenem and/or metronidazole with warfarin may  augment 
its anticoagulant effects.  There have been man y reports of increases in the anticoagulant 
effects of orall y administered anticoagulant agents, including warfarin, in patients who are 
concomitantly  receiving antibacterial agents.  The risk may  vary  with the underly ing infection, 
age, and general status of the patient so that the contribution of the antibiotic to the increase in 
international normalised ratio (INR) is di fficult to assess.  In addition to the standard study  
safet y laboratory  assessments, frequent monitoring of the INR should be performed during 
and shortly  after co -administration of study  therapy  with an oral anticoagulant agent, as per 
local practice.  
In vitro, avibactam is a substrate of organic anion transporter (OAT) 1 and OAT3, which 
might contribute to the active uptake from the blood compartment and, thereb y its 
excretion. Probenecid (a potent OAT inhibitor) inhibits this uptake by  55% to 70% in v itro 
and, therefore, has the potential to alter the elimination of avibactam when co -dosed.  Since a 
clinical interaction stud y of avibactam and probenecid has not been conducted, co -dosing of 
avibactam with probenecid is not recommended.  Probenecid interferes with the active tubular 
secretion of meropenem, resulting in increased plasma concentrations of meropenem.  
Therefore, co -
administration of probenecid with meropenem is not recommended.  There is 
significant drug -drug interaction between meropenem and valproic acid or sodium valproate; 
therefore co -administration of meropenem and valproic acid or sodium valproate should be 
avoided.
A number of unfavourable reactions with other drugs are known for ceftazidime.  
Contraindications and known drug interact ions for ceftazidime are summarised in Table 6.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
67(88)Table 6 Contraindications and drug -drug interactions
Ceftazidime Concurrent administration with chloramphenicol should be avoided.  Chloramphenicol has been shown to be 
antagonistic to Î² -lactam antibiotics, including ceftazidime.
Concurrent administration with aminoglycoside antibiotics or potent diuretics s uch as furosemide may result in 
nephrotoxicity.  Because of potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics, renal function 
should be carefully monitored, especially if higher dosages of aminoglycosides are to be administered or if therapy is 
prolonged.
Concurrent administration with combined oral oestrogen/progesterone contraceptives may result in lower oestrogen 
reabsorption and reduced efficacy of these contraceptives secondary to the effects of ceftazidime on gut flora.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
68(88)Ciproflo xacin Administration in pregnant or lactating women is contraindicated.
Concurrent administration with tizanidine is contraindicated.
Concurrent administration with methotrexate is not recommended; methotrexate may inhibit renal tubular transport 
of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate -
associated toxic reactions.
Concurrent administration with theophylline decreases theophylline clearance, resulting in elevated serum 
theophylline levels and increased risk of a patient developi[INVESTIGATOR_336312].
Concurrent administration with caffeine or pentoxifylline (oxpentifylline) may raise serum concentrations of these 
xanthine derivatives.
Concurrent adm inistration with antacids containing magnesium hydroxide or aluminium hydroxide may reduce the 
bioavailability of ciprofloxacin by [CONTACT_45848] 90%.
Concurrent administration with probenecid interferes with renal secretion of ciprofloxacin and increases 
ciprofloxacin serum concentrations.
Concurrent administration with phenytoin may result in increased or reduced serum levels of phenytoin; monitoring 
of drug levels is recommended.
Concurrent administration with warfarin may augment its anticoagulant effects. The risk may vary with the 
underlying infection, age, and general status of the patient so that the contribution of a fluoroquinolone to an 
increased INR is difficult to assess.  It is recommended that INR be monitored frequently during and shortly after 
co-administration of ciprofloxacin with an oral anticoagulant agent.
Concurrent administration with ropi[INVESTIGATOR_336313] 
60%.  Monitoring of ropi[INVESTIGATOR_11122]- related side effects and dose adjustment as appropriate is recommended during and 
shortly after co- administration with ciprofloxacin.
Concurrent administration with clozapi[INVESTIGATOR_336314] N -desmethylclozapi[INVESTIGATOR_050], a 
metabolite, by [CONTACT_45848] 29% and 31%, respectively.   Clinical surveillance and appropriate adjustment of clozapi[INVESTIGATOR_336315] -administration with ciprofloxacin are recommended.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
69(88)Amoxicillin -
clavulanic acidConcurrent administration with probenecid decreases the renal tubular secreti on of amoxicillin but does not delay 
renal excretion of clavulanic acid.  Concurrent use with amoxicillin -clavulanic acid may result in increased and 
prolonged blood concentrations of amoxicillin.  Co -administration of probenecid is not recommended.
Concur rent administration of amoxicillin with oral anticoagulants may result in abnormal prolongation of 
prothrombin time (increased INR).  Appropriate monitoring should be undertaken when anticoagulants are 
prescribed concurrently with amoxicillin -clavulanic ac id.  Adjustments in the dose of oral anticoagulants may be 
necessary to maintain the desired level of anticoagulation.
Concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both 
drugs as compared t o patients receiving amoxicillin alone.
Concurrent administration of oral contraceptives and amoxicillin -clavulanic acid may affect intestinal flora, leading 
to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contrac eptives.
High urine concentrations of amoxicillin may result in false- positive reactions when testing for the presence of 
glucose in urine using ClinitestÂ®, Benedict's solution, or Fehling's solution.  Since this effect may also occur with 
amoxicillin- clavulanic acid, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be 
used.
Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total 
conjugated estriol, estriol -glucuronide , conjugated estrone, and estradiol has been noted.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Nu mber 2
Date 07 March 2017
70(88)Meropenem No specific medicinal product interaction studies other than probenecid have been conducted.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of 
meropenem with the effect of increasing the elimination half -life and plasma concentration of meropenem.  Caution 
is required if probenecid is co -administered with meropenem.
The potential effect of meropenem on the protein binding of other me dicinal products or metabolism has not been 
studied.  However, the protein binding is so low that no interactions with other compounds would be expected on the 
basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it i s co-administered with carb apenem agents 
resulting in a 60 to 100 % decrease in valproic acid levels in about 2days. Due to the rapid onset and the extent of 
the decrease, co -administration of valproic acid/sodium valproate/valpromide with carbapenem age nts is not 
considered to be manageable and therefore should be avoided.
Oral anti coagulants
Simultaneous administration of antibiotics wit h warfarin may augment its anti coagulant effects. There have been 
many r eports of increases in the anti coagulant effects of orally administered anti coagulant agents, including warfarin 
in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, 
age and general status of the patient so that the contribution of the an tibiotic to the increase in INR is difficult to 
assess. It is recommended that the INR should be monitored frequently during and shortly after co -administration o f 
antibiotics with an oral anti coagulant agent.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
71(88)7.8.1 Drug -drug interaction s
Drug -antibiotic interactions occur with man y medications commonly prescribed in children, 
particularl y those drugs with a narrow therapeutic index.  Therefore, extra caution is advised 
in the event that concomitant medications need to be changed or added for children.
7.8.2 Other concomitant treatment
Other medication other than that described above, which is considered necessary  for the 
patient â€™s safet y and well -being, may  be given at the discretion of the Investigator and recorded 
in the appropriate sections of the CRF.
8. STATISTICAL ANALYSES
8.1 Statistical considerations
All personnel involved with the analy sis of the study  will remain blinded until database -lock.  
Analy ses will be performed by  [CONTACT_244979].  
A comprehensive Statistical Anal ysis Plan (SAP) will be prepared prior to the randomisation 
of the first patient to the study .  An y subsequent amendments to the SAP will be documented, 
with final amendments completed prior to unblinding of the data for the analy sis.
8.[ADDRESS_415525] 
72hours (3 full day s, ie, 9 doses) of study  treatment (deemed to be evaluable patients).  
Patients will be randomised 3:[ADDRESS_415526] 60 and 20 evaluable patients, respectivel y, are required in the 
CAZ -AVI plus metronidazole and meropenem groups.
The proposed sample size is based on the probability  of observing a â€˜rareâ€™ safet y event.  
Safety  dat
a from this study and from Study  D4280C00016 for cUTI will be combined for 
analysis.  As a total of at least 120 patients will be treated with CAZ -AVI in both studies 
combined, when assuming an underl ying incidence rate of 3% for a specific â€˜rareâ€™ event, t his 
will ensure that the probability  of observing such an event in at least 1 patient treated with 
CAZ -AVI exceeds 95%.
Patients will be allocated to 1 of 4 cohorts based on age. Randomisation will be stratified as 
follows:
ï‚·Cohort 1: At least 15:5 evaluab le patients aged from 12 y ears to <18 years
ï‚·Cohort 2: At least 15:5 evaluable patients aged from 6 y ears to <12 years
ï‚·Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 y ears
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
72(88)ï‚·Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 y ears,
comprising Cohorts 4a and 4b as follows:
ï€­Cohort 4a: P atients aged from 1 year to <2 years
ï€­Cohort 4b: Patients aged from 3 months to <[ADDRESS_415527] been recruited having been diagnosed with complicated appendicitis is 90%.
8.3 Definitions of analysis sets
The anal ysis of data will be based on different analy sis sets according to the purpose of 
analysis, ie, for safet y and efficacy.  The decision regarding validity
 of data for each of the 
analysis sets will be based on a blinded review of data, which will occur prior to declaring 
database lock.
8.3.1 Safety an alysis set
The Safet y anal ysis set will include all randomised patients who received any  amount of IV 
study  therapy  (ie, CAZ -AVI plus metronidazole or meropenem).  For the Safety  anal ysis set, 
patients will be included in all outputs according to the study treatment they  actuall y received.
8.3.[ADDRESS_415528]â€™s dosing profile will be reviewe d by 
[CONTACT_336355].
8.3.[ADDRESS_415529] 
1 ceftazidime and/or avibactam plasma measurement available.
8.3.4 Efficacy analysis sets
The efficacy anal ysis of data in this study  will be based on 4 analy sis sets of patients ( intent -
to-treat [I TT], microbiological ITT [micro -ITT], clinically  evaluable [CE] .and 
microbiologicall y evaluable [ME] analysis sets) as defined in Sections [IP_ADDRESS] to [IP_ADDRESS].  
Each of these anal ysis sets will be defined separately  for each of the visits at which efficacy  is 
assessed.
Patients who receive both study  therapi[INVESTIGATOR_336316].  
Patients in the ITT, micro -ITT, CE,and ME analy sis sets will be summarised according to the 
randomised treatment assignment .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
73(88)[IP_ADDRESS] Intent -to-treat analysis set 
The ITT anal ysis set will include all patients who have been assigned a randomised treatment.
[IP_ADDRESS] Microbiological intent -to-treat analysis set
The micro -ITT analysis set will include all randomised patients who have a baseline pathogen 
known to cause cIAI.
[IP_ADDRESS] Clinicall y evaluable analysis set
The CE anal ysis set is defined separatel y at the end of [ADDRESS_415530] a confirmed diagnosis of cIAI; patients must also meet the following specific 
conditions:
ï‚·Have received at least 48 hours of IV stud y drug in order to be considered an evaluable 
clinical failure, un less deemed a clinical failure based on a treatment -limiting AE
ï‚·Have received at least 72 hours of IV stud y drug in order to be considered an evaluable 
clinical cure
ï‚·Have been evaluated at the End of 72 hours and at the  specific visits of EOIV, EOT, 
and TOC with a clinical response of cure or failure (or have been assessed as a clinical 
failure before the planned assessment visit), or for LFU, have been evaluated with a 
clinical response of sustained cure or relapse
ï‚·Had no important protocol deviations tha t would affect assessment of efficacy
[IP_ADDRESS] Microbiologically evaluable analysis set
The ME anal ysis set is defined separatel y at the end of 72 hours of stud y treatment, and at 
each of the EOIV, EOT, TOC, and LFU visits.  It includes all patients meeting the fol lowing 
criteria:
ï‚·Are a subset of all randomised patients who have received an y amount of IV study  
drug and have a confirmed diagnosis of cIAI
ï‚·Have received at least 48 hours of IV stud y drug in order to be considered an evaluable 
clinical failure, unless d eemed a clinical failure based on a treatment- limiting AE
ï‚·Have received at least 72 hours of IV stud y drug in order to be considered an evaluable 
clinical cure
ï‚·At the specific visit had a microbiological response which was not indeterminate (note; 
presumed eradication or presumed persistence is acceptable)
ï‚·Had no important protocol deviations that would affect assessment of efficacy
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280 C00015
Edition Number 2
Date 07 March 2017
74(88)ï‚·Have at least 1 ty pi[INVESTIGATOR_336317] t hat is susceptible to both study  agents 
(CAZ- AVI and meropenem)
8.4 Outcome measures for analyses
8.4.1 Primary outcome variables
The primary  outcome variables are for safet y and tolerability as assessed b y:
ï‚·AEs and SAEs
ï‚·Cephalosporin class effects and additional AEs
ï‚·Vital signs (pulse, blood pressure, respi[INVESTIGATOR_2842], temperature)
ï‚·Physical examination
ï‚·Laboratory  parameters
ï‚·ECG
ï‚·CrCl 
8.4.2
Secondary outcome variables
ï‚·Plasma concentrations of CAZ and AVI will be listed and summarised b y nominal 
sampling time window using appropriate descriptive statistics
ï‚·Clinical response at End of 72 hoursâ€™ treatment, EOIV, EOT, and TOC
ï‚·Microbiological response at EOIV, EOT, TOC, and LFU
ï‚·Clinical relapse at LFU
ï‚·Emergent infections
8.5 Methods for statistical analyses
8.5.1 Analysis of the primary variables
The primary  variables are for safet y and tolerability.  No inferential statistical tests will be 
performed for an y safety variables.  All data will be presented b y treatment group and b y 
cohort (and also by  [CONTACT_336356]).  Descriptive statisti cs (number, mean, standard 
deviation [SD], median, minimum, and maximum) will be provided for continuous variables, 
and counts and percentages will be presented for categorical variables.  Demographic data ,
other baseline characteristic data , and concomita nt medications will also be summarised.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
75(88)Safety  assessments will be based on AE reports and the results of vital sign measurements, 
physical examinations, ECGs and clinical laboratory  tests.  For each safet y variable, the last 
assessment made prior to the f irst dose of stud y drug will be defined as the baseline.  All 
safet y data collected from this study  up to the LFU visit will be presented within the Safety  
analysis set ( as defined in Section 8.3.1) by  [CONTACT_336357] (ie, for 
CAZ -
AVI plus metronidazole or meropenem), irrespective of whether the patient switched to 
oral therap y.  Key safet y data reported up to the LFU visit will al so be summarised for the 
Safety evaluable analysis set (ie, those who received at least 72 hours of study  treatment as 
defined in Section 8.3.2
) by [CONTACT_336328].
Safety  data from this study  and from Study  D4280C00016 for cUTI will be combined for 
analysis.  This anal ysis of combined safety  data will be reported separately of the data from 
this study , and will include the summaries of top-line data using the same formats as presented 
for this study .
[IP_ADDRESS] Adverse events
The incidence of AEs will be tabulated and reviewed for potential significance and clinical 
importance.  AEs oc curring before the start of study  treatment will be reported separatel y from 
all other AEs.  AEs occurring from the start of the first infusion of IV study  therapy  will be 
summarised by  [CONTACT_336358] s ystem organ class using the latest version of Medi cal 
Dictionary  for Regulatory  Activities (MedDRA) vocabulary .
All recorded AEs will be listed and tabulated b y system organ class, preferred term and for 
each cohort.  
Summaries and listings of AEs leading to death, SAEs and AEs leading to discontinuation of 
study  treatment will also be presented.  Summaries will also be presented by  [CONTACT_160814] I V 
study  therapy  and b y AE intensity .
The number of patients reporting AEs among the following topic groups of AEoSI , for which 
prior review has identified groupi[INVESTIGATOR_336318] , will also be tabulated by  [CONTACT_9084]:
ï‚·Liver disorder
ï‚·Diarrhoea
ï‚·Hypersensitivity /anaphy laxis
ï‚·Haematological disorder
ï‚·Renal disorder
The number of patients with at least 1 AE within each AEoSI topic group will be presented b y 
study  treatment group, together with a further presentation of the AE incidence rates for each 
PT within each AEoSI topic group.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
76(88)[IP_ADDRESS] Other safety data
Summaries and listings of data for vital signs, clinical laborat ory and urinaly sis laboratory  
tests, ECGs and phy sical examination findings will be presented.  Appropriate data will be 
summarised for the observed value at each scheduled assessment and for the corresponding 
change from Baseline.  
For clinical laborator y tests, listings of patient data will also flag up an y abnormal or 
out-of
-range values.  Potentially  clinicall y significant changes in the laboratory test 
parameters will also be identified, listed, and summarised at scheduled visits.  This summary  
will p resent data for patients meeting the criteria at any time during the study up to the EOT 
visit, and separatel y at any time up to the LFU visit.  Clinical laboratory data will be reported 
in Sy stÃ¨me International units.
The following number of patients meet ing the following criteria at an y time during the study 
up to the LFU visit will be assessed: (maximum ALT â‰¥3Ã—ULN or maximum AST â‰¥3Ã—ULN) 
and(maximum total bilirubin â‰¥2Ã—ULN).  The AST, ALT, total bilirubin elevations can occur 
at an y time in the specific r eview period and do not need to occur simultaneously .
For ECG variables, the QT correction factor will be based on both the Bazett and Fridericia 
formulae (QT cB and QT cF).  Categorical summaries of absolute QT, QT cB and QT cF values 
(â‰¥450 ms, â‰¥480 ms, â‰¥500 ms) and change from Day  1 (Baseline) values in QT, QT cB and 
QT cF values ( â‰¥30ms, â‰¥60ms), and additionally  the number and percentage of patients who 
have a post -baseline value of â‰¥500 ms with a change from Day  1 of â‰¥60ms will be presented 
by [CONTACT_3148], vi sit and cohort.  The number of patients meeting these criteria at an y time after 
the start of study  treatment until the LFU visit will also be summarised by  [CONTACT_336359].
The number and percentage of patients with CrCl in the following ranges: <30 mL/min, 30 to 
50 mL /min, >50 mL /min will be tabulated at each of the TOC and LFU visits for each 
treatment group.
8.5.2 Analysis of the secondary variable(s)
No inferential statistical tests will be performed for any  secondary  variables.
[IP_ADDRESS] Pharmacokinetic outcome variables
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by  
[CONTACT_336331].  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by  [CONTACT_336360] (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean Â±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 to 4 bwill be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  The 
actual dosing and plasma sampling times will be used for the anal ysis.  The developed 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibac tam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
77(88)population PK model may  be used to conduct simulations to determine probability  of PK/PD 
target attainment to help to justify  the CAZ -AVI dose regimens for paediatric patients with 
cIAI.  A stand- alone population PK modelling and simulat ion analy sis plan will be prepared 
and the results will be reported in a stand -alone report outside of the CSR.
Avibactam and ceftazidime PK parameters derived from population PK analy sis and potential 
PK/PD relationships will be reported separatel y.
[IP_ADDRESS] Clini cal outcome definitions
Clinical response outcomes will be summarised by [CONTACT_765], treatment ,and cohort in each of the 
CE and ME anal ysis sets at End of 72 hoursâ€™ treatment, EOIV, EOT, TOC, and LFU , as well 
as the ITT and micro -ITT anal ysis sets .  
A clinical failure occurring at the EOIV timepoint or 
later will alway s be carried forward to any  subsequent assessment time.  The Blinded 
Observer will make the assessment of clinical outcome.
For each baseline pathogen identified with sufficient frequenc y, the number and percentage of 
patients in each treatment group and cohort classified as having a favourable clinical outcome 
for the particular pathogen will also be summarised.
Clinical Outcome at End of 72 hours 
The clinical outcome categories at the End of 72 hours are defined in Table 7.  Favourable 
clinical outcomes are clinical improvement and clinical cure.
Table 7 Clinical outcome assessments at End of 72 hours
Outcom e Definition
Clinical Cure Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement Patients who are improving but not enough to switch to oral therapy and are still 
on IV study drug at End of 72 hours and meet the following criterion:
- Absence of new signs and symptoms, and improvement in at least 
1symptom or sign (ie, fever, pain, tenderness, elev ated WBCs, 
elevated CRP) from Baseline, and with no w orsening of any symptom 
or sign
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
78(88)Table 7 Clinical outcome assessments at End of 72 hours
Outcom e Definition
Clinical Failure Patients who meet any of the follow ing criteria:
- Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or w orsening in 
signs and symptoms of cIAI that requires alternative non -study 
antimicrobial therapy
- Discontinuation of study drug due to an AE and requirement for 
alternative non -study antimicrobial therapy for cIAI
- Death in whi ch cIAI is contributory
- Postsurgical wound infections defined as an open wound with signs of 
local infection such as purulent exudates, erythema, or w armth that 
requires additional antibiotics and/or nonroutine wound care
- Patients who are improving but not enough to switch to oral therapy 
and are still on IV study drug at End of 72 hours and who fail to meet 
the following criterion:
Absence of new signs and symptoms, and improvement in at least 
1symptom or sign (ie, fever, pain, tenderness, elevated WBCs, 
elevated CRP) from Baseline, and with no w orsening of any symptom 
or sign
Indeterminate Study data are not available for evaluation of efficacy for any reason, including:
- Death in which cIAI is clearly non -contributory
- Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow -up)
Within each analy sis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the anal ysis set)
Clinical Outcome at EOIV
The clinical outcome categories at EOIV are defined in Table 8.  Favourable clinical outcomes 
are clinical improvement and clinical cure.  A clinical failure at EOIV will be carried forward 
to the EOT and TOC visits.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
79(88)Table 8 Clinical outcome assessments at EOIV
Outcom e Definition
Clinical Cure Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement Patients who switch to oral therapy and meet all of the following criteria at 
EOIV:
- Afebrile (temperature â‰¤38.0Â°C) for at least [ADDRESS_415531] 1 symptom or sign (ie, 
fever, pain, tenderness, elevated WBCs, elevated CRP) from Baseline 
and w orsening of none.
Clinical FailureaPatients who meet any of the follow ing criteria:
- Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or w orsening in 
signs and symptoms of cIAI that requires alternative non -study 
antimicrobial therapy
- Discontinuation of study drug du e to an AE and requirement for 
alternative non -study antimicrobial therapy for cIAI
- Death in which cIAI is contributory
Indeterminate Study data are not available for evaluation of efficacy for any reason, including:
- Death in which cIAI is clearly no n-contributory
- Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow -up)
aA clinical failure at EOIV will be carried forward to EOT and TOC.
Within each analy sis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the anal ysis set)
Clinical Outcome at EOT
The clinical outcome categori es at EOT are defined in Table 9.  A favourable clinical outcome 
is clinical cure.  A clinical failure at EOT will be carried forward to the TOC visit .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidim e-avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
80(88)Table 9 Clinical outcome assessments at EOT
Outcom e Definition
Clinical Cure Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical FailureaPatients who meet any of the follow ing criteria:
- Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or w orsening in 
signs and symptoms of cIAI that requires alternative no n-study 
antimicrobial therapy
- Discontinuation of study drug due to an AE and requirement for 
alternative non -study antimicrobial therapy for cIAI
- Death in which cIAI is contributory
Indeterminate Study data are not available for evaluation of efficac y for any reason, including:
- Death in which cIAI is clearly non -contributory
- Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow -up)
aA clinical failure at EOT will be carried forward to TOC.
Within each analy sis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure 
(Number of patients in the anal ysis set)
Clinical Outcome at TOC
The clinical outcome categories at TOC are defined in Table 10.  A favourable clinical 
outcome is clinical cure.  Clinical response b y pathogen at TOC will also be determined for 
each pathog en isolated at Baseline.
Table 10 Clinical outcome assessments at TOC
Outcom e Definition
Clinical Cure Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Failure Patients who meet either of the following criteria:
- Incomplete resolution or worsening of cIAI signs or symptoms or 
development of new signs or symptoms requiring alternative 
non-study antimicrobial therapy
- Death in which cIAI is contributory
Indeterminate Study data are not available for evaluation of efficacy for any reason, including:
- Death in which cIAI is clearly non -contributory
- Extenuating circumstances precluding classification as a cure or failure 
(eg, patien t lost to follow -up)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
81(88)Within each analy sis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure 
(Number of patients in the anal ysis set)
Clinical Outcome at LFU
Each patient who was considered clinicall y cured at TOC will be reassessed at LFU b y the 
Blinded Observer for evidence of clinical relapse of cIAI sy mptoms.  The clinical outcome 
categories at LFU are defined in Table 11.  A favourable clinical outcome at L FU is sustained 
clinical cure.
Table 11 Clinical outcome assessments at LFU
Outcom e Definition
Sustained Clinical Cure Continued favourable response, defined as resolution of all acute signs and 
symptoms of cIAI and no further antimicrobial therapy is required
Clinical Relapse Patients who meet either of the following criteria:
- Reappearance or w orsening of signs and symptoms of cIAI that 
requires further antimicrobial therapy and/or surgery
- Death after TOC in which cIAI is contributory
Indeterminate Study data are not available for evaluation of efficacy for any reason, including:
- Death in which cIAI is clearly non-contributory
- Extenuating circumstances precluding classification as sustained 
clinical cure or clinical relapse (eg, patient lost to follow -up)
Note: Clinical outcome at LFU will only be assessed in patients who were considered clinically cured at T OC.
The proportion of patients with clinical relapse at the LFU visit will be summarised b y 
treatment and cohort in both the CE and ME anal ysis sets.
Within each analy sis set, the proportion of patients with a clinical relapse is defined using the 
following formula: 
Number of patients with clinical relapse
(Number of patients in the anal ysis set)
[IP_ADDRESS] Microbiological response assessments
The proportion of patients wit h a favourable per -patient microbiological response (ie, 
eradication or presumed eradication) will be summarised b y treatment and cohort in the 
micro- ITT and ME anal ysis set sat the EOIV, EOT, TOC and LFU visits.
The per -pathogen microbiological outcome ca tegories are defined in Table 12.  Favourable 
microbiological outcomes are eradication or presumed eradication.  Baseline pathogens will 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
82(88)be determined based on central laboratory  data (see Section 5.2.1 for details on culture and 
organism identification).  Rules for determination of pathogens will be described in the SAP.  
In order for a patient to have a favourable microbiological response, the outcome for each 
baseline pathogen must be favourable (eradicated or presumed eradicated).  If the outcome for 
any pathogen is unfavourable (persistence o r presumed persistence), the patient will be 
considered to have an unfavourable microbiological response.
Table 12 Per-pathogen microbiological outcome categories
Outcom e Definition
Eradication Source specimen demonstrate sabsence of the original baseline pathogen
Presumed eradication Source specimen not available to culture, and the patient assessed as a clinical 
cure or sustained clinical cure or (for EOIV only) clinical improvement
Persistence Source specimen demonstrates continued presence of the original baseline 
pathogen
Persistence with increasing 
MICaSource specimen demonstrates continued presence of the original baseline 
pathogen with a minimum inhibitory concentratio n (MIC )value â‰¥4-foldlarger 
than th at observed for the baseline pathogen
Presumed persistence Source specimen was not available to culture and the patient w as assessed as a 
clinical failure or clinical relapse
Indeterminate Source specimen was not available to culture and the patientâ€™s clinical outcome 
was assessed as indeterminate
aPersistence with increasing MIC is a subset of the Persistence outcome.
For patients who have a microbiological outcome of persistence or presumed persistence at 
the EOIV timepoint or later , this outcome will be carried forward to subsequent visits.
[IP_ADDRESS] Emergent infections
Pathogens first appearing after Baseline (â€œemergent infectionsâ€) until the LFU in patients with 
a baseline pathogen are categorised in Table 13 and these will be summarised separatel y by 
[CONTACT_323923].
Table 13 Emergent infections
Infection category Definition
Superinfection Isolation of a new pathogen or pathogens (other than the original 
baseline pathogen[s]) from intra- abdominal cultures which is 
accompanied by [CONTACT_336361] .
New infection Isolation of a new pathogen or pathogens (other than the original 
baseline pathogen[s]) from intra- abdominal cultures which is 
accompanied by [CONTACT_336362] d after EOT.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
83(88)The proportion of patients with an emergent infection (and b y infection category) will be 
summarised by  [CONTACT_336363].
9. STUDY AND DATA MANAG EMENT 
9.[ADDRESS_415532] of all individuals involved in the study  
(medical, nursing and other staff).
9.[ADDRESS_415533] regular contacts with the study  site, 
including visits to:
ï‚·Provide information and support to the Investigator(s)
ï‚·Confirm that facilities remain acceptable
ï‚·Confirm that the investigational team is adhering to the protocol, that data are being 
accuratel y and timel y recorded in the CRFs, that biological samples ar e handled in 
accordance with the Laboratory  Manual and that study  drug accountabilit y checks are 
being performed
ï‚·Perform source data verification (a comparison of the data in the CRFs with the 
patientâ€™s medical records at the hospi[INVESTIGATOR_7117], and othe r records relevant to the 
study ) including verification of informed consent/assent of participating patients.  This 
will require direct access to all original records for each patient (eg, clinic charts)
ï‚·Ensure withdrawal of informed consent/assent to the use of the patientâ€™s biological 
samples is reported and biological samples are identified and disposed of/destroy ed 
accordingl y, and the action is documented, and reported to the patient.
The [COMPANY_008] representative will be available between visits if t he Investigator(s) or other 
staff at the centre needs information and advice about the study  conduct.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
84(88)9.2.1 Source data
Refer to the Clinical Study Agreement (CSA) for location of source data.
9.2.2 Study agreements
The Principal Investigator [INVESTIGATOR_144109]/the centre should comply  with all the terms, conditions, and 
obligations of the CSA, or equivalent, for this study .  In the event of any  inconsistency  
between this Clinical Study  Protocol and the CSA, the terms of Clinical Study  Protocol shall 
prevail with respect to the conduct of the stud y and the treatment of patients and in all other 
respects, not relating to study  conduct or treatment of patient s, the terms of the CSA shall 
prevail.
Agreements between [COMPANY_008] or [COMPANY_008]â€™s representatives, and the Principal 
Investigator [INVESTIGATOR_336319] -related procedures can take place, or patient
s 
are enrolled.
9.2.3 Archiving of study documents
The Investigator follows the principles outlined in the CSA.
9.3 Study timetable and end of study
The end of the stud y is def ined as â€˜the last visit of the last patient undergoing the study â€™.
The study  is expected to start in Q [ZIP_CODE] and to end by  Q3 2017.
The study  may  be terminated at individual centres if the study  procedures are not being 
performed according to Good Clinical Practice (GCP), or if recruitment is slow.  [COMPANY_008] 
may also terminate the entire study  prematurel y if concerns for safet y arise within this study  
or in any  other study  with CAZ -AVI.
9.4 Data management by [CONTACT_336364] s ystem will be used for data collection and query  handling.  The 
Investigator will ensure that data are recorded on the CRFs as specified in the study  protocol 
and in accordance with the instructions provided.
The Investigator ensures the accuracy , completeness, and timeliness of the data recorded and 
the provision of answers to data queries according to the CSA.  The I nvestigator will sign the 
completed CRFs.  A copy of the completed CRFs will be archived at the study  site.
Data management will be performed b y PRA , according to the C linical Informatics Plan.  
Adverse events and medical/surgical history
 will be classified according to the terminology  of 
the latest version of the MedDRA.  Medications will be classified according to the 
[COMPANY_008] Drug Dictionary .  All coding will be pe rformed b y the PRA coding group.  Data 
queries will be raised for inconsistent, impossible or missing data.  All entries to the study  
database will be available in an audit trail.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
85(88)The data will be validated as defined in the Clinical I nformatics Plan and Edit Specifications 
Document.  Qualit y control procedures will be applied to each stage of data handling to ensure 
that all data are reliable and have been processed correctl y.  The Clinical Informatics Plan will 
also clarify  the roles and responsibilities of the various functions and personnel involved in 
the data management process.
When all data have been coded, validated, signed and locked, clean file will be declared.  An y 
treatment revealing data may  thereafter be added and the final database will be locked.
Serious Adverse Event Reconciliation
Serious adverse event reconciliation reports are produced and reconciled with the patient 
safet y database and/or the investigational site.  SAE reconciliation between safet y data and 
clinical data will be perfor med by  [CONTACT_29663].  The frequency  depends on the expected volume of 
SAE reports and will be defined in the AE/SAE Reconciliation Plan.
Management of external data
The data collected through third party  sources will be obtained and reconciled against study  
data.
10. ETHICAL AND REGULATORY REQUIREMENTS
10.[ADDRESS_415534] their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP, applicable regulatory  requirements 
and the [COMPANY_008] policy  on Bioethics and Human Biological Samples.
10.2 Patient data protection
The I CF/Assent Form will incorporate (or, in some cases, be accompanied by  a separate 
document incorporating) wording that complies with relevant data protection and privacy  
legislation.
10.3 Ethics and regulatory review
An Independent Ethics Committee (I EC)/ Institutional Review Board (I RB) should approve 
the final study  protocol, including the final version of the ICF, Assent Form, and any  other 
written information and/or 
materials to be provided to the patients.  The Investigator will 
ensure the distribution of these documents to the applicable IEC/I RB, and to the study  site 
staff.
The opi[INVESTIGATOR_336320]/IRB should be given in writing.  The Investigator should submit the 
written approval to PRA before enrolment of an y patient into the study . 
The IEC/I RB should approve all advertising used to recruit patients for the study .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
86(88)PRA should approve an y modifications to the I CF and Assent Form that are needed to meet 
local require ments.
If required b y local regulations, the protocol should be re -approved by [CONTACT_6179]/I
RB annuall y.
Before enrolment of an y patient into the study , the final study  protocol, including the final 
version of the ICF, and Assent Form, is approved by  [CONTACT_336365] y or a 
notification to the national regulatory  authority  is done, according to local regulations.
PRA will handle the distribution of any  of these documents to the national regulatory  
authorities.
PRA will provide Regulatory  Authorit ies, IECs/IRBs and Principal Investigators with safet y 
updates/reports according to local requirements.
Each Principal Investigator [INVESTIGATOR_336321]/IRB with reports of an y 
serious and unexpected adverse drug reactions from any  other st udy conducted with the I P.  
PRA will provide this information to the Principal Investigator [INVESTIGATOR_153215]/she can meet these 
reporting requirements.
10.4 Informed consent
The Principal Investigator(s) at each centre will:
ï‚·Ensure each patient's parent(s) or other legall y acceptable representative(s) and patient 
when applicable (if age appropriate according to local regulations) is given full and 
adequate oral and written information about the nature, purpose, possible risk and 
benefit of the stud y
ï‚·Ensure each patien t's parent(s) or other legall y acceptable representative(s) and patient 
when applicable (if age appropriate according to local regulations) is notified that they  
are free to discontinue from the study  at an y time
ï‚·Ensure that each patient's parent(s) or other legally acceptable representative(s) and 
patient when applicable (if age appropriate according to local regulations) is given the 
opportunity  to ask questions and allowed time to consider the information provided
ï‚·Ensure each patientâ€™s parent(s) or ot her legall y acceptable representative(s) provides 
signed and dated informed consent and patient (if age appropriate according to local 
regulations) provides signed and dated assent before conducting an y procedure 
specificall y for the study
ï‚·Ensure the origi nal, signed I CF(s) and Assent Form (if age appropriate according to 
local regulations) is/are stored in the Investigatorâ€™s Study  File
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
87(88)ï‚·Ensure a cop y of the signed I CF(s) and Assent Form (if age appropriate according to 
local regulations) is/are given to the patientâ€™s parent(s) or other legally  acceptable 
representative(s)
ï‚·Ensure that an y incentives for patients who participate in the study as well as an y 
provisions for patients harmed as a consequence of study participation are described in 
the ICF(s) and As sent Form (if age appropriate according to local regulations) that is 
approved b y an IEC/I RB
10.5 Changes to the protocol and Informed Consent Form
Study  procedures will not be changed without the mutual agreement of the International 
co-ordinating Investigator and [COMPANY_008].
If there are an y substantial changes to the stud y protocol, then these changes will be 
documented in a stud y protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study  Protocol).
The amendment is to be approved b y the relevant IEC/IRB and if applicable, also the national 
regulatory  authorit y approval, before implementation.  L ocal requirements are to be followed 
for revised protocols.
[COMPANY_008] will distribute an y subsequent amendments and new ve rsions of the protocol to 
each Principal Investigator (s). For distribution to IEC/IRB see Section 10.3
.
If a protocol amendment requires a change to a centreâ€™s ICF and/or Assent Form, [COMPANY_008] 
and the centreâ€™s IEC/IRB are to approve the revised I CF and/or Assent Form (if applicable) 
before the revised form(s) is/are used. 
If local regulations require, an y administrative change will be communicated to or approved 
by [CONTACT_336366]/IRB.
10.[ADDRESS_415535] [COMPANY_008] 
immediately  if contact[CONTACT_426]  a regulatory  agency  about an inspection at the centre.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Global Revised Clinical Study Protocol
Drug Substance Ceftazidime -avibactam   
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
88(88)11. LIST OF REFERENCES
European Commission 2008
European Commission.  Ethical considera tions for clinical trials on medicinal products 
conducted with the paediatric population: Recommendations of the ad hoc group for the 
development of implementing guidelines for Directive 2001/20/EC relating to good clinical 
practice in the conduct of clini cal trials on medicinal products for human use.  2008.  
Available from: http://ec.europa.eu/health/files/eudralex/vol -10/ethical_considerations_en.pdf.
Howie 2011
Howie SR.  Blood sample volumes in child health research: review of safe limits.  Bull World 
Health Organ 2011;89:46-53.
Schwartz et al 2009
Schwartz GJ, MuÃ±oz A, Schneider MF, Mak RH, Kaskel F, Warady
 BA, et al.  New equations 
to estimate GFR in children with CKD .  J Am Soc Nephrol 2009 Mar;20(3):[ADDRESS_415536] KPC -2 carbapenemase and 
Enterobacteriaceae expressing KPC carbapenemases.  J Antimicrob Chemother 
2009;64(2):326 -9.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix B
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20January  2015
Appendix B
Additional Safety Information
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix B
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(3)FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE)
Life threatening
â€˜Life-threateningâ€™ means that the subject was at immediate risk of death from the AEas it 
occurred or it is suspected that use or continued use of the product would result in the 
subject â€™s death.  â€˜Life -threateningâ€™ does not mean that had an AEoccurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospi[INVESTIGATOR_336322] a serious AE
, although the reasons 
for it ma y be (eg, bronchospasm, lary ngeal oedema).  Hospi[INVESTIGATOR_2144]/or surgical 
operations planned before or during a stud y are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study , provided that it did not dete riorate in an 
unexpected way  during the study .
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may  not be immediately  life threatening or result in 
death, hospi[INVESTIGATOR_11956], disability  or incapacit y but may  jeopardize the subject or may  require 
medical intervention to prevent one or more outcomes listed in the definition of serious.  
These should usually  be considered as serious.
Simply  stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Examples of such events are:
ï‚· Angioedema not severe enough to require intubation but requiring iv hy drocortisone 
treatment
ï‚· Hepatotoxic ity caused b y paracetamol (acetaminophen) overdose requiring 
treatment with N -acetylcysteine
ï‚· Intensive treatment in an emergency  room or at home for allergic bronchospasm
ï‚· Blood d yscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsions that do not result in hospi[INVESTIGATOR_11956]
ï‚· Development of drug dependency  or drug abuse.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix B
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(3)A GUIDE TO INTERPRETING THE CA[LOCATION_003]LITY QUESTION
The following factors should be considered when deciding if there is a â€œreasonable 
possibility â€ that an AE may  have been caused by  [CONTACT_33641].
ï‚· Time Course.  Exposure to suspect drug.  Has the subject actuall y received the 
suspect drug?  Did the AE occur in a reasonable temporal relationship to the 
administration of the suspect drug?
ï‚· Consistency  with known drug profile.  W as the AE consistent with the previous 
knowledge of the suspect drug (pharmacology  and toxicology ) or drugs of the same 
pharmacological class? OR could the AE be anticipated from its pharmacological 
properties?
ï‚· Dechallenge experience.  Did the AE resolve o r improve on stoppi[INVESTIGATOR_96699]?
ï‚· No alternative cause.  The AE cannot be reasonably explained b y another aetiology 
such as the underly ing disease, other drugs, other host or environmental factors.
ï‚· Rechallenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? [COMPANY_008] would not normally  recommend or support 
a rechallenge.
ï‚· Laboratory  tests.  A specific laboratory  investigation (if performed) has confirmed 
the relationship?
A â€œre asonable possibilityâ€ could be considered to exist for an AE where one or more of these 
factors exist.
In contrast, there would not be a â€œreasonable possibility â€ of causality  if none of the above 
criteria apply  or where there is evidence of exposure and a reasonable time course but an y 
dechallenge (if performed) is negative or ambiguous or there is another more likely cause of 
the AE.
In difficult cases, other factors could be considered such as:
ï‚· Is this a recognised feature of overdose of the drug?
ï‚· Is ther e a known mechanism?
Ambiguous cases should be considered as being a â€œreasonable possibility â€ of a causal 
relationship unless further evidence becomes available to refute this.  Causal relationship in 
cases where the disease under study  has deteriorated du e to lack of effect should be classified 
as no reasonable possibility .
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix C
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January  2015
Appendix C
International Airline Transportation Association (IATA) 6.2 Guidance 
Document
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix C
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(3)LABELLING AND SHIPME NT OF BIOHAZARD SAMP LES
International Airline Transportation Association (IATA) classifies biohazardous agents into 
3categories (http://www .iata.org/whatwedo/cargo/dangerous_goods/infectious_substance
s.htm ). For transport purposes the classification of infectious substances according to risk 
groups was removed from the Dangerous Goods Regulations (DGR) in the 46th edition 
(2005).  Infectiou s substances are now classified either as Category  A, Category  B or Exempt.  
There is no direct relationship between Risk Groups and categories A and B.
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability , life-threatening or fatal disease in 
otherwise healthy  humans or animals.  Category  A pathogens are eg, Ebola, L assa fever virus:
ï‚· are to be packed and shipped in accordance with IATA Instruction 602.
Category B I nfectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category  A.  Category  B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) t ypes 1 and 2.  They  are assigned the following UN 
number and proper shippi[INVESTIGATOR_72919]:
ï‚· UN 3373 â€“Biological Substance, Category  B
ï‚· are to be packed in accordance with UN3373 and IATA 650
Exempt - all other materials with minimal risk of containing pathogens
ï‚· Clinical trial samples will fall into Category  B or exempt under IATA regulations
ï‚· Clinical trial samples will routinely  be packed and transported at ambient 
temperature in IATA 650 compliant packaging 
(http://www. iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.
htm)
ï‚· Biological samples transported in dry ice require additional dangerous goods 
specification for the dry -ice content
ï‚· IATA compliant courier and packaging materials should be used for packing and 
transportation and packing should be done b y an IATA certified person, as 
applicable
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix C
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(3)ï‚· Samples routinely  transported by  [CONTACT_76477] a safe and appropriate way  to 
contain an y risk of infection or contamination by [CONTACT_73015]/containment materials at all times.  The IATA [ADDRESS_415537] or rail transport 
is used.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
Appendix D
Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilir ubin - Hyâ€™s Law
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(6)TABLE OF CONTENTS PAGE
TABLE OF CONTENTS ......................................................................................... 2
1. INTRODUCTION ................................................................................................... 3
2. DEFIN ITIO NS................................................................
......................................... 3
3. IDENTIFICATION OF PO TENTIAL HYâ€™S LAW CAS ES................................... 3
4. FOLLOW -UP.......................................................................................................... 4
4.1 Potential Hy â€™s Law Criteria not met ........................................................................ 4
4.2 Potential Hy â€™s Law Criteria met .............................................................................. 4
5. REVI EW AND ASSESSMEN T OF POTENT IAL HYâ€™S LAW CASES ............... 5
6. REFERENCES ................................................................
........................................ 6
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(6)1. INTRODUCTION
During the course of the study  the Investigator will remain vigilant for increases in liver
biochemistry .  The investigator is responsible for determining whether a patient meets 
potential Hy â€™s Law (PHL) criteria at an y point during the stud y.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review an d assessment of cases meeting PHL criteria to agree whether Hy â€™s Law (HL) criteria 
are met.  HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry  other than Drug Induced Liver Injury  (DILI) caused by  [CONTACT_336367] (IMP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with sta ndard safet y reporting processes.
2. DEFINITIONS
Potential Hyâ€™s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) â‰¥ 3x Upper L imit of 
Normal (ULN) and Total Bilirubin (TBL) â‰¥ 2xULN irrespective of an increase in Alkaline 
Phosphatase (ALP), at any  point during the study  following the start of study  medication.  The 
elevations do not have to occur at the same time or within a specified time frame.
Hyâ€™s Law (HL)
AST or ALT 
â‰¥ 3x UL N andTBL â‰¥ 2xULN, where no other reason, other than the IMP, can 
be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, 
viral hepatitis, another drug.  The elevations do not have to occur at the same time or within a 
specified time frame.
For PHL and HL the elevation in transaminases must precede or be coincident with (i.e. on the 
same day ) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
3. IDENTIFICATION OF PO TENTIAL HYâ€™S LAW CAS ES
In order to identify  cases of PHL  it is important to perform a comprehensive review of 
laborat ory data for any  patient who meets any  of the following identification criteria in 
isolation or in combination:
ï‚· ALT â‰¥ 3xULN
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
4(6)ï‚· AST â‰¥ 3xUL N
ï‚· TBL â‰¥ 2xUL N
When the identification criteria are met from laboratory  results the Investigator will without 
delay :
ï‚· Determ ine whether the patient meets PHL  criteria (see Section 2of this Appendix 
for definition) b y reviewing laboratory  reports from all previous visits (including 
both central and local laboratory  results)
The Inves tigator will without delay  review each new laboratory  report and if the identification 
criteria are met will:
ï‚· Notify  the [COMPANY_008] representative
ï‚· Determine whether the patient meets PHL  criteria (see 
Section 2of this Appendix 
for definition) b y reviewing laboratory  reports from all previous visits
ï‚· Promptly  enter the laboratory  data into the laboratory  CRF
4. FOLLOW-UP
4.1 Potential Hyâ€™s Law Criteria not met
If the patient does not meet PHL  criteria the Investigator w ill:
ï‚· Perform follow -up on subsequent laboratory  results according to the guidance 
provided in the Clinical Study  Protocol.
4.2 Potential Hyâ€™s Law Criteria met
If the patient does meet PHL  criteria the Investigator will:
ï‚· Notify  the [COMPANY_008] representative wh o will then inform the central Study  Team 
The Study  Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the stud y patientsâ€™ follow -up and the continuous review of data.  Subsequent to 
this contact [CONTACT_737] w ill:
ï‚· Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically  
indicated 
ï‚· Investigate the etiology  of the event and perform diagnostic investigations as 
discussed with the Study  Physician
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
5(6)ï‚· Complete the three Liver CRF Modules as information becomes available 
ï‚· If at an y time (in consultation with the Study Physician) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures
5. REVIEW AND ASSESSMEN T OF POTENTIAL HYâ€™S LAW 
CASES
The instructions in this Section should be followed for all cases where PHL criteria are met.
No later than [ADDRESS_415538] and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequentl y 
whether the AE meets the criteria for a SAE:
ï‚· If the alternative explanation is notan AE, record the alternative explanation on the 
appropriate CR F
ï‚· If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF 
accordingl y and follow the AZ standard processes
If it is agreed that there is no explanation that would explain the AL T or AST 
and TBL 
elevations other than the IMP:
ï‚· Report an SA E (report term â€˜Hy â€™s Lawâ€™) according to [COMPANY_008] standard 
processes. 
ï€­The â€˜Medically  Importantâ€™ serious criterion should be used if no other serious 
criteria apply
ï€­As there is no alternative explanation for the HL case, a causalit y assessment of 
â€˜relate dâ€™ should be assigned.
If, there is an unavoidable delay , of over 3 weeks, in obtaining the information necessary  to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation until such time as an
informed decision can be made:
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix D
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
6(6)ï‚· Report an SAE (report term â€˜Potential Hy â€™s Lawâ€™) apply ing serious criteria and 
causality  assessment as per above
ï‚· Continue follow -up and review according to agreed plan.  Once the necessary  
supplementary  information is obtained, repeat the review and assessment to 
determine whether HL criteria are met.  Update the SAE report according to the 
outcome of the review
6. REFERENCES
FDA Guidance for Industry  (issued July  2009) â€˜Drug- induced liver injury : Premarketing 
clinical evaluatio nâ€™:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances
/UCM174090.pdf
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix E
Drug Substance Ceftazidime -avibactam 
Study Code D4280C00015
Edition Number 1
Date 20 January  2015
Appendix E
Tanner Staging of Development
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix E
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015Edition Number 1
Date 20 January 2015
2(4)TANNER STAGING OF DEVELOPMENT IN GIRLS
Once the onset of puberty has begun, the resulting sequence of somatic and physiologic 
changes gives rise to the sexual maturity rating, or Tanner sta ges.  Figure [ADDRESS_415539] the somatic changes which are also described in Table 1 .
Figure 1 Sexual maturity ratings (2 to 5) of pubic hair changes in adolescent 
girls. (Courtesy of , MD,  
 
 England)
[COMPANY_003] [COMPANY_003]
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix E
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015Edition Number 1
Date 20 January 2015
3(4)Figure 2 Sexual maturity ratings (1 to 5) of breast changes in a dolescent girls. 
(Courtesy of , MD,  
, 
England)
[COMPANY_003] [COMPANY_003]
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)
Clinical Study Protocol Appendix E
Drug Substance Ceftazidime -avibactam
Study Code D4280C00015
Edition Number 1
Date 20 Jan uary 2015
4(4)Table [ADDRESS_415540]. Geme J, Schor N, Behrma.n RE. Nelson Textbook of Pediatrics . 
19th ed. Philade lphia, PA. Elsevier 2011; Part XIII:649 -51. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)